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Commentaries

Being “Normal”

336

In certain areas it is easy to
define “normal.” In other areas it is
challenging or impossible.  In general,
if given a choice, we prefer normality
although we sometimes like to stand
out.  For things that can be measured
we can define normal, assuming
that the measurement has a “normal
distribution” curve, as being within
two standard deviations of the mean.  
For many things we want to be “better
than average”, though, smarter, better
looking, faster, stronger, more creative,
more musical, more artistic, more
clever, nicer, more successful, etc.  
These are “normal” desires.  
We
can’t
define
normal
appearance, nor can we define
normal behavior.   We know what
seems “freakish” in appearance and
we have a fairly uniform agreement
on what behaviors are clearly beyond
the normal, and probably to a
lesser extent, an agreement on what
behaviors are considered “abnormal.”  
In non-statistical terms, we might
consider some behaviors to be “fringe”
behaviors, borderline acceptable,
perhaps eccentric and “different” but
not clearly “abnormal.”
Almost all of us have dreaded “not
fitting in.”   We are an impressively
conforming species.   Dress codes,
work habits, gender stereotypes, social
intercourse are quite strictly defined
in the various cultures of the world
and deviation is not generally well
accepted.
It is this fairly straightforward
and banal view of the world, which I
think is shared by most people, that is
challenged in a recent book, One of Us.
The author, a non-physician, reports
on the world of Siamese twins.   Her
thesis is that Siamese twins, sharing a
world so close, have a life experience
that is so closely shared that no one else
can possibly imagine it.  This shared
life is so special and wonderful that
it overcomes the obvious difficulties
that having a shared body requires.  
A point stated repeatedly, that only a
single set of Siamese twins who were
adults ever decided to undergo a
surgical separation.  This observation,
Medicine and Health / Rhode Island

the author suggests, indicates that
Siamese twin adults prefer their life,
see themselves as quite special, and
cannot see themselves as benefiting
from a separation.  
This author expands her argument
by arguing that people with congenital
malformations, such as cleft palate, do
not necessarily  lead improved lives as
a result of early repair.  She notes that
over the years, with further experience
with cleft palate repair, more social
behavior supports have been provided
to the children and their families, and
that some people who did not have
this surgery are glad that they didn’t.
I read the review of this book in the
New England Journal of Medicine and
bought it right away.  I love iconoclastic
thinking.   I love to be intellectually
provoked, to have to rethink my basic
assumptions on almost anything.  One
either strengthens old convictions by
seeing them survive another attack,
or one may have to modify old beliefs
and “grow.”   Sometimes though, one
is disappointed.  I recently was shown
a mathematical “proof ” by my teenage
son, purporting to show that 1=2.  
The various steps in the proof are
self-evident, starting with the “given,”
that a=b, then progressing through
a few simple arithmetic steps, the
penultimate one being division by ab.  Unfortunately a-b=0, and division
by zero is not allowed.   The proof
that 1=2 founders on an unacceptable
step.   The book above lacks what
psychologists call “face validity.”  
Asking  Siamese twins whether they’d
prefer to be separate is almost akin
to asking someone if they’d rather
never have been born.   It is almost
unthinkable, I suspect, to imagine a
life so totally different than the one
you’d led, to imagine two points of
view when you’ve always had one, to
imagine a freedom unimaginable, to
live “on your own” once you’re an adult
who never had such an opportunity.  
The book makes clear that one of the
largest preoccupations of the general
public is how these twins have sexual
relations (some have had families) or
even toilet themselves.

On National Public Radio
several years ago I heard a program on
dwarfism and abortion.   The world
of the achondroplastic dwarf, the
most common form of dwarfism, is,
as one would imagine, quite different
than the world of larger, “normal”
people.   The issue being considered
was the ethics of an achondroplastic
couple having an abortion if the
fetus was normal and not affected by
dwarfism, since it was reported that
achondroplastic dwarf couples prefer
to have children like themselves.   I
have no idea if other groups of people
with genetic disorders, for example,
people with inherited deafness, feel
the same way. Perhaps this could be
true for Siamese twins.  I suspect that
most people, especially doctors, who
routinely interact with many more
people in much more intimate settings
than most people, would find the
concept of Siamese twins refusing to
be separated as lacking “face validity.”  
Currently the operations are dictated
by the parents, who, like most of us, see
very little of value in maintaining the
connection between the two bodies.  
“Normal” trumps “special,” especially
when “special” does not look in any
way appealing.  How can anyone argue
that the surgery should await adult
decision-making, when the surgery
becomes more dangerous AND the
personalities become increasingly
formed by the unique circumstances?
On the other hand, maybe there’s a
power in two twins sharing a life.
Bipolar
(manic
depressive
disorder) disease has been associated
with increased creativity.   If bipolar
disease could be “cured” (not simply
controlled), but only in childhood, and
this resulted in diminished creativity
in adults, would we do it? And would
it matter if we knew the child was
or was not destined to be “creative?”  
“Curing” conjoined twins is now often
possible.  Other life altering “cures” of
non-fatal disorders and anomalies lie
in the near future.  Ethical issues will
undoubtedly abound.

Joseph H. Friedman, MD

The Gaols that Spawn Disease
From bitter, intimate experience, Oscar Wilde once wrote:
I know not whether the laws be right,
Or whether laws be wrong;
All that we know who lie in Gaol
Is that the wall is strong.
Wilde had been imprisoned in Reading Gaol (in the
US, spelled jail) from 1895 to 1897; and upon his release ,
he changed his name to Sebastian Melmoth, fled in haste to
France, and within years died an embittered, lonely person.  
British prisons were probably no worse than those on
continental Europe.  But it required the literary passions of a
Dickens, a Wilde or some of the more contemporary Russian
writers, to convey the true dehumanizing horrors of gaols, jails
or gulags.
Charles Dickens frequently described the infamous
prisons of London. Talking of the wretched Newgate Gaol:
“But, the gaol was a vile place in which most kinds of
debauchery and villainy were practiced, and where dire
diseases were bred, that came into court with the prisoners,
and sometimes rushed straight from the dock at my Lord
Chief Justice himself, and pulled him off the bench.  It had
more than once happened that the judge in the black cap
pronounced his own doom as certainly as the prisoner’s, and
even died before him.”
Dickens was referring, in general, to that “dire disease”
known as gaol fever which was the dreaded pestilence
infesting jails, army encampments, concentration camps,
refugee centers, orphan asylums, alms houses and the steerage
compartments of passenger ships.  The disease had been known
variously as famine fever, ship fever, Irish ague and Hungarian
disease (since, on many occasions, it had decimated the
Holy Roman Empire armies during their periodic invasions
of Hungary.) Gaol fever is a contagious disorder, caused by
Rickettsial germs, and is transmitted from person to person by
body lice. It is a communicable disease, now called epidemic
typhus, which prospers in desperately inhuman conditions of
filth and overcrowding.
But Dickens was referring to something more specific
than the disease which had killed far more soldiers than all the
battlefield casualties caused by gunfire, and far more English
prisoners than all of the sanctioned hangings at Newgate
prison.
The year was 1577 and Queen Elizabeth was in the
nineteenth year of her lengthy reign. The English realm was
relatively quiet, the threat of a Spanish armada would not
materialize for another decade, and while smallpox, syphilis
and bubonic plaque continued to be endemic, this had not
been a year of notable epidemic intensity of any of these three
pestilences.
In July of 1577, in Oxfordshire, the periodic Assize (a
word of Latin origin meaning an official court session) was
convened in the Old County Hall on New Road. Presiding
over the court was Sir Robert Bell, Lord Chief Baron of the
province; and in attendance was Sir Robert D’Oyly, Lord
High Sheriff.  On trial was a local bookseller from the town
of Oxford, one Rowland Jenkes, described in court records as

“a saucy, fouled-mouthed bookseller who was imprisoned for
scandalous words uttered against the Queen.”
During the trial of Mr. Jenkes, brief though it was, note was
made of the nauseating stench issuing from the subterranean
caverns beneath the courtroom, where about three hundred
prisoners were closely held while awaiting their summary
judgments issued by the court then in session.   Gaol fever,
with its terrible headaches, hectic fevers, blotchy skin rashes,
delirium and high mortality rate had spread rapidly through
these huddled masses of prisoners. And within forty days,
about 300 prisoners had succumbed to the fever.  The Lord
Chief Baron, the Lord High Sheriff as well as their entourages,
had also fallen victim to gaol fever. While they did not share
the crowded dungeons beneath the courtroom, the body lice
nesting in the prisoners’ clothing had inevitably spread to the
velvet robes of those proffering judgment.
By the 18th Century, gaol fever became a known
occupational hazard for court attendants –even judges.   As
long as the English legal system required that prisoners be
afforded a day in court, facing the judge, the hazard existed
of the prisoner’s lice-infected body contaminating the judge’s
robes.   And so, periodically, English magistrates learned,
through personal encounter, the travails of epidemic typhus.
The 1577 trial of Rowland Jenkes, with its spread of gaol fever
to the judge, was likely the first to enter the history books. It is
now referred to as the Black Assize.
Newgate Prison, one of London’s more notorious gaols,
was completely rebuilt in the 19th Century in the hopes of
reducing the risk of typhus contagion.  But this worthy end was
not achieved until hygienic measures were finally undertaken
to reduce or eliminate lice infestation.
The draconian laws that imprisoned a Mr. Jenkes for illconsidered words about a ruling monarch or an Oscar Wilde
for intemperate verbiage which his trial declared to be libel,
have since become more tolerant. Prisons, at least in Western
nations, have become less dungeons and more impersonal
lockups with relatively sanitary facilities,  Typhus, therefore,
may not be a looming threat in American prisons, but
whenever incarceration conditions sink to barbaric levels, the
likelihood will be high of a return to the circumstances which
foster epidemic typhus.
An eminent physician-bacteriologist, Hanz Zinnser,
wrote a book on the history of typhus.   This 1934 classic,
Rats, Lice and History, offered a comprehensive review of the
tragic impact of typhus fever upon the many European armies,
including Napoleon’s Grand Army in its ill-considered invasion
of Russia, and particularly the destructive role of typhus in
devastating the trench-bound troops of World War I, especially
the Eastern Front armies struggling to survive under terribly
primitive circumstances.  Millions died of typhus during that
conflict as well as during the civil wars and revolution which
overtook Russia after 1917.
Zinnser concluded with these prophetic words:  “Typhus
is not dead.  It will live on for centuries, and it will continue to
break into the open whenever human stupidity and brutality
give it a chance, as most likely they occasionally will.”
Stanley M. Aronson, MD
Vol. 88 No. 10 October 2005

337

Introduction: Women’s Health
Sharon Marable, MD, MPH, and Maureen G. Phipps, MD, MPH
This edition of Medicine & Health/Rhode Island
represents a partnership between the Rhode Island
Department of Health (HEALTH) Office of Women’s
Health and the Brown University / Women & Infants
Hospital National Center for Excellence on Women’s
Health (CoE).  Together, we envision a Rhode Island where
all women have the opportunity to achieve an optimal state
of health and wellness.
The HEALTH Office of Women’s Health works
to elevate the health status of women and girls by
coordinating internal  HEALTH efforts and collaborating
statewide with agencies that advocate for women and girls.
Since   being designated a   CoE by the US Department
of Health and Human Services in 2003, the mission
of the Brown University / Women & Infants Hospital
National Center of Excellence in Women’s Health has
been to foster participation and contributions from the
community to improve health and health care for all
women.  This mission is accomplished through promoting  
representation of women from all backgrounds in medical
leadership positions, enhancing professional education,
expanding innovative women’s health research, educating
the community and providing a model of quality clinical
care for all women.
This edition highlights the collaborative effort between
HEALTH and the CoE to improve women’s health in
Rhode Island, by educating practitioners about key clinical
issues facing their women patients. Articles focus on the
unique psycho-social pressures women experience which
impact upon their well-being, and medical conditions that
present differently or more commonly in women compared
to men.  Authors also recognize medical conditions where
women do not receive the same level of treatment as men
and where clinical trials have not effectively included
women to establish appropriate treatment regimens.
Dr. Barbara Roberts   in “Gender Specific Aspects
of Cardiovascular Disease” points out that women with
cardiovascular disease often do not present with classic
symptoms of chest pain.  She  outlines the lack of evidence
in the current guidelines for prescribing statins in women
for the primary prevention of coronary events.  Dr. Rosanna
Moura discusses Irritable Bowel Syndrome (IBS), a
complex  disorder of unknown cause and cure, which affects
a higher proportion of women than men.   She outlines
criteria for the diagnosis of   IBS and options physicians
can take to alleviate its symptoms.   Understanding that
many women have concerns around weight gain and
incontinence, especially as they bear children or become
older, two articles focus on these issues.   Drs. Suzanne
Phelan and Rena Wing provide recommendations for
the promotion of healthy lifestyles and weight control for
women, particularly during pregnancy and menopause.  
Drs. Vivian Sung and Deborah Myers review the economic
impact of stress urinary incontinence (SUI) and advances
in surgical options.
Many of the columns have a Women’s Health focus.
“Images in Medicine,”   by Drs. Beth Plante and Troilus
Plante, illustrates radiological findings in a woman with
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abdominal pain. Doctors of Pharmacy Sarah G. Kachur,
Christine L. Hannan, and Kristina E. Ward discuss
“Antidepressant-Induced Weight Gain” in Advances in
Pharmacology,
Dr. Jennifer Gass describes a vision of the future of
breast surgery in “Creative Clinician.”  Drs. Linsay Madom
and Lori Boardman explain the utility of HPV testing in
the context of cervical cancer screening in Advances in
Laboratory Medicine. Columnists from Quality Partners  
of RI and the Rhode Island Department of Health focus on
women’s health.  
In summary, this edition brings together clinicians,
researchers, public health officials and health policy experts
to discuss issues that face our women patients.  Elevating
the health status of women is essential to improving the
health of the entire  community. We hope that you enjoy
this special edition and the information gives you new
insights regarding the medical care of the women in your
office practice.
Correspondence:
Sharon  Marable, MD, MPH
RI Department of Health
3 Capitol Hill, Room 408
Providence, RI 02908
Phone: (401) 222-5353
E-mail: sharon.marable@health.ri.gov

Maureen G. Phipps, MD, MPH
Women & Infants Hospital
101 Dudley Street
Providence, RI  02905
Phone (401) 274-1122 x2834
E-mail: mphipps@wihri.org

Sharon Marable, MD, MPH, is Medical Director,
Office of Women’s Health Rhode Island Department of
Health, and Clinical Assistant Professor, Community Health
Brown Medical School.
Maureen G. Phipps, MD, MPH, is Director, Brown
University/Women & Infants Hospital National Center
of Excellence in Women’s Health, and Assistant Professor,
Departments of Obstetrics and Gynecology and Community
Health, Brown Medical School.
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“The Art of the Book,” will feature works from the
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Gender-Specific Aspects of
Cardiovascular Disease
Barbara H. Roberts, MD
Misconceptions about women
and heart disease date back almost 250
years to William Heberden, an eighteenth century British physician who
first described the symptom of angina
pectoris in 1768. He noted, “ Males
are most liable to this disease, especially such as have past their fiftieth year.
I have seen nearly a hundred people
under this disorder, of which number
there have been three women.”  James
Herrick in 1912 described the symptoms of acute myocardial infarction
(MI) and noted that nearly all cases
were in men past middle age.1
Only in the last few decades have
the medical profession and the public
begun to appreciate the magnitude
of the problem of cardiac disease in
women.   Since 1984 more women
than men have died of atherosclerotic
cardiovascular disease (ASCVD) annually in the United States.a2 Despite
this, women are diagnosed and treated
less aggressively than men,b3,4 and are
woefully underrepresented in clinical
trials.
As more attention has been paid
to the problem of ASCVD in women
we have learned more about gender
differences in clinical presentation
which influence the way women are
approached and treated. We have
known since the early publications
of the Framingham Heart Study that
women tend to present with angina
pectoris and men with either MI or
sudden cardiac death. The Framingham Heart Study was among the first
to note the increased likelihood of “silent myocardial infarction” in women
compared to men.
The classic symptoms of MI are
severe, substernal chest pain associated with dyspnea, diaphoresis and a
feeling of impending doom. However,
these symptoms, while typical in men,
may not be experienced as frequently
in women. A study reported in 2003
on prodromal and acute symptoms in
515 female survivors of acute MI.3,5
Prodromal symptoms were present in
95% of women for a month or more

pre-infarct and the most frequent were
unusual fatigue (70.7%) and sleep
disturbance (47.8%). The most frequent acute symptoms were shortness
of breath (57.9%), weakness (54.8%),
unusual fatigue (42.9%), cold sweat
(39%), dizziness (39%), back discomfort (37%) and high chest discomfort
(27.7%). 43% of patients in this series
experienced no chest discomfort at all,
and the authors postulated that lack of
significant chest pain may be a major
reason that women have more unrecognized MIs.

“…the data
reveal NO
evidence that
treating
women without
clinically
apparent
vascular disease
with statins, even
those at high
risk, lowers their
risk of cardiac
events.”
The greater mortality rate of
women with MIs has been attributed
to the fact that they tend to be older
than men at the time of presentation. However, a retrospective study
of 155,565 women and 229,313 men
with acute MI enrolled in the National Registry of Myocardial Infarction 2,
found that a higher hospital mortality rate occurred only among younger
women.4,6 Women under age 50 had a
6.1% hospital mortality rate compared
to 2.9% for same aged men. The sex
difference in mortality rates decreased
with increasing age and was not significant after age 74. The authors also
found more co-morbid conditions,
higher pulse rates and lower systolic

blood pressures among younger women than among younger men but not
in older women compared to older
men. Of interest, despite these findings, younger women were less likely
than younger men to present with
ST-segment elevation, and while they
had similar infarct locations, creatine
kinase levels and left ventricular ejection fractions, they had higher rates of
hypotension, shock, heart failure and
bleeding.
Women undergoing coronary
artery bypass grafting (CABG) have
also been noted to have a higher mortality than men. This has traditionally been ascribed to their older age.
However, just as is the case with MI,
an analysis of 51,187 patients (30%
women) who had CABG between
1993 and 1999 found that younger
women had higher hospital mortality than men (3.4% versus 1.1% for
women and men < 50 years of age
and 2.6% versus 1.1% for women and
men 50 to 59 years of age).5,7 Among
patients 80 years of age or older there
was no significant difference in mortality (9.0% in women versus 8.3%
in men). Younger women undergoing
CABG had more risk factors and comorbid conditions than age-matched
men but multivariate analysis found
that this explained less than 30%
of the mortality difference between
younger men and women.
This mortality difference persisted after adjustment for body size
and remains largely unexplained. Also,
women in this study had angiographically less severe coronary artery disease (CAD) and better left ventricular (LV) function in all age categories.
In contrast, a review of the results of percutaneous coronary intervention (PCI) in 20016,8 found
that the apparent gender difference
in outcomes was negated after adjustment for body size. Using data from
the National Cardiovascular Network
Database on 109,708 patients (33%
women) who underwent PCI between
1994 and 1998, researchers found that
Vol. 88 No. 10 October 2005
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women had higher risks for stroke,
vascular complications and repeat inhospital procedures, even after risk-adjustment. They had higher unadjusted
hospital mortality rates (1.8% versus
1.0%) but after correction for body
size, gender was not found to be an independent predictor of mortality.
Perhaps the most striking gender
disparity with regard to cardiovascular
disease is the under-representation of
women in clinical trials. Physicians
are urged to practice “evidence-based
medicine” but when it comes to women, the evidence is often lacking, particularly in the area of drug treatment
of hyperlipidemia. The guidelines for
treatment of hyperlipidemia take no
account of gender (except in the different cut points for the normal level
of HDL-cholesterol). But there is reason to believe that they should. Over
the past few decades several large,
randomized, placebo-controlled trials have shown the benefit of statins
(and to a lesser extent fibrates) in both
primary and secondary prevention of
cardiovascular events.
Of the three large primary prevention trials of statin use, two included women:  the AFCAPS/TexCAPSg9
and ASCOT-LLA8,10 trials. (Overall,
women made up 12.5% of the 23,505
subjects enrolled in the three large primary prevention trials of statins. The
WOSCOPS10,11 trial enrolled only
men.) The AFCAPS/TexCAPS trial
was undertaken to determine if treatment with lovastatin in subjects without clinically evident ASCVD with
average total cholesterol (TC) and
LDL- cholesterol (LDL-C) levels,
but below average HDL-cholesterol
(HDL-C), would lead to a reduction
in the risk of first major coronary
event. This was defined as fatal or nonfatal MI, unstable angina, or sudden
cardiac death. AFCAPS/TexCAPS enrolled 997 women (15% of the study
population). The ages of participants
ranged from 45 to 73 years for the
men and 55 to 73 years for the women. Overall, the trial found a statistically significant benefit of treatment
with a 37% relative risk reduction in
the likelihood of first major coronary
event. However, on gender-specific
analysis, while 13 primary end point
events occurred in women on placebo
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and 7 events occurred in women on
lovastatin, this was not a statistically
significant difference, given the small
numbers of events. (In contrast there
were 170 events in men on placebo
compared to 109 events in men on
lovastatin.)  
The ASCOT-LLA was a trial in
hypertensive patients without known
ASCVD but with at least three other
risk factors who were randomized to
either placebo or atorvastatin and followed for the occurrence of the composite primary end point of non-fatal
MI or fatal coronary heart disease.  
Participants’ ages ranged from 40 to
79 years. ASCOT-LLA enrolled 1,942
women (19% of the study population). Overall the trial found a statistically significant 36% relative risk
reduction in the likelihood of the primary end point. However, on genderspecific analysis there were 19 primary
events in the women on atorvastatin
and 17 events in the women on placebo, again, not a statistically significant
difference. (In contrast there were 81
primary events in men on atorvastatin
and 137 events in men on placebo.)
Summarizing the results of these two
primary prevention trials of statin use,
there were 30 events in 1,461 women
on placebo and 26 events in 1,478
women on statins, a difference that is
not statistically significant (p = 0.56).
Despite this lack of evidence
for the efficacy of statins in the primary prevention of coronary events
in women, both the Adult Treatment Panel III10,12 and the more recent “Evidence-Based Guidelines for
Cardiovascular Disease Prevention in
Women”11,13 recommend statin use in
women with LDL-C levels above a certain value based on level of risk, even
in the absence of diagnosed ASCVD.
However, the data reveal NO evidence
that treating women without clinically
apparent vascular disease with statins,
even those at high risk, lowers their
risk of cardiac events.
When it comes to secondary
prevention with statins, the data in
women are also not as compelling as
they are in men. During the past two
decades five large secondary prevention trials of statins in coronary heart
disease included men and women.
Women made up 25% of the 43, 957

subjects enrolled in the 4S trial12,14, the
Heart Protection Studym15, the Cholesterol and Recurrent Events Trial14,16,
the LIPID Trial15,17 and the PROSPER
Trial16,18. All of these studies showed
a statistically significant decrease in
the relative risk of coronary events in
statin treated compared to placebo
treated men. In contrast, gender-specific analysis did not find a statistically
significant decrease in risk of cardiac
events in women in two of these five
trials (LIPID and PROSPER), while
the other three did demonstrate benefit in women.
Why the disparity between the
findings with regard to the efficacy of
statins in men versus women, at least
with respect to primary prevention? It
might be due to the small numbers of
women in the statin trials. However,
there is an alternative explanation. Elevations of LDL-C do not appear to
be as potent a risk factor in women as
they are in men. Even among kindred
with Type II Familial Hyperlipoproteinemia, the onset of coronary artery
disease in women lags 10 to 15 years
behind that of men with equivalent
and very high levels of LDL-C.17,19
More than twenty years ago, women
were noted to have significantly less
cholesterol in small dense LDL and
more in large LDL than men.18,20
Small dense LDL-C particles are more
atherogenic than large fluffy LDL-C
particles and since women, at least
before the menopause, have more of
the latter, it is likely that equivalent
levels of LDL-C are less atherogenic in
women than men.
In support of this hypothesis,
a follow-up study of 2,406 men and
2.056 women enrolled in the Lipid
Research Clinics program who were
free of vascular disease and aged 40
to 64 years at entry, followed for an
average of 19 years, found that only elevated non HDL-C and low HDL-C
significantly predicted cardiovascular
disease (CVD) mortality in women,
whereas TC, LDL-C, non HDL-C
and low HDL-C all predicted CVD
mortality in men.19,21
More recently, it has been suggested that the LDL-C goal for very
high-risk patients be lowered to 70
mg/dl or less20,22 based on the findings
of the PROVE-IT trial,21,23 which en-

rolled 4162 patients (22% women)
with acute coronary syndromes to
receive either 40 mg. of pravastatin
or 80 mg. of atorvastatin. The subjects in the atorvastatin group, who
achieved a median LDL-C level of 62
mg/dl, had a statistically significant
16% relative risk reduction in the
rate of the primary end point compared to the pravastatin treated group
who achieved a median LDL-C level
of 95 mg/dl. The benefit of intensive
therapy with high dose atorvastatin
was consistent across all prespecified
subgroups, including women.
The preventive guidelines for
women also recommend treating
non-HDL-C and low HDL-C with
a fibrate or niacin if they are abnormal once the LDL-C goal is achieved.
There is not only a paucity of data
to support this, there are no data.
The two controlled trials of fibrates
(the Helsinki Heart Study22.24 and
VA-HIT23,25) that showed benefit in
reducing cardiac events enrolled only
men.
Where do these studies leave us
with respect to primary prevention
in women? Unfortunately, we do not
have evidence-based answers to this
question. For premenopausal women with no other risk factors than
an LDL-cholesterol above the current threshold, statins have not been
shown to decrease the risk of cardiac
events. There is clearly no harm in
counseling ALL patients on weight
control, regular exercise and heart
healthy diet. The use of statins in ostensibly healthy young women should
probably be reserved for those with
Familial Hypercholesterolemia where
LDL-C values are in the range of 300
to 400 mg/dl. In addition, their use
is contraindicated during pregnancy
and lactation; most package inserts
state that: “STATINS SHOULD BE
ADMINISTERED TO WOMEN
OF CHILDBEARING AGE ONLY
WHEN SUCH PATIENTS ARE
HIGHLY UNLIKELY TO CONCEIVE AND HAVE BEEN INFORMED OF RISKS, we know little
about their long-term effects. If we
are proposing to treat healthy, lowrisk women for decades it behooves us
to be certain that efficacy is beyond
doubt and that benefits outweigh the

risks. We simply do not know this
with regard to statin (or fibrate/niacin)
use in young women who do not have
vascular disease.
The recently reported results of
the trial of aspirin for primary prevention of cardiovascular disease in
women24,26   demonstrate the fallacy
of assuming that results in men can
be generalized to women. Among 39,
875 healthy women 45 years of age or
older who were randomized to either
100 mg of aspirin every other day or
placebo there was a 24% reduction
in the risk of ischemic stroke but no
decrease in the risk of fatal or non-fatal MI or death from cardiovascular
causes. (However, in women 65 or
older aspirin significantly reduced the
risk of both ischemic stroke and MI.)
These results in women contrast with
those of the Physicians’ Health Studyy27
which found that aspirin significantly
reduced the risk of MI in that all-male
cohort but had no significant effect on
the risk of stroke. The accompanying
editorial26,28 concludes, “…clinical research…needs always to account for
the evolutionary biology of sex.”
The Institute of Medicine also
noted the importance of taking sex
into account: “Sex matters. Sex, that
is, being male or female, is an important basic human variable that should
be considered when designing and
analyzing studies in all areas and at all
levels of biomedical and health-related
research.”27,29
In summary there are genderspecific differences in cardiovascular
disease including age at presentation,
risk factor weighting, response to medicines, symptoms and mortality. More
research needs to be done to elucidate
gender differences and to determine the
safest, most efficacious preventive strategies and treatments in both sexes.
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IRRITABLE BOWEL SYNDROME
Rossana Moura, MD
Irritable Bowel Syndrome
(IBS) affects up to 20% of the US
population,with a 2:1 female-to-male
ratio.1,2 IBS accounts for approximately
3 million physician visits annually,3
12% of office visits to primary care
physicians, 28% of all referrals to
gastroenterologists;1 and $1.7 billion
to $10 billion in direct annual medical
costs (excluding medications) and up
to $20 billion in indirect costs (e.g.,
lost work productivity and missed
workdays).4,5
The higher prevalence of the
disorder in American women might
reflect their increased willingness to
seek medical advice.2 Other factors
influencing   consultation in IBS
include access to care, symptom
severity, fear of cancer, psychiatric comorbidities and personality factors,
including learned illness behavior and
recent life events.
Definition
Although first recognized nearly
2 centuries ago, IBS remains widely
misunderstood by both patients and
physicians. Because it is a functional
disorder, no organic or structural
abnormality can be identified. The lack
of objective findings can be frustrating
and the differential diagnosis broad.
For that reason, a number of symptombased criteria have been developed to
try to simplify and standardize the
diagnostic approach to IBS; in 1978 the

Manning criteria6  were published, and
most recently, the Rome II criteria.  
(Table) 17
Clinical Symptoms
IBS is a chronic condition
and consists of abdominal pain or
discomfort, associated with changes in
bowel pattern (constipation, diarrhea
or alternation of both). Patients with
IBS are usually categorized, according
to their primary bowel habits, as
having IBS-C (less than three bowel
movements per week, presence of
hard stools, straining and lumpy
stools), IBS-D (more than three bowel
movements per day, loose watery stools,
and urgency), or IBS-A (alternating
constipation and diarrhea).8 Women

“...in most cases
of IBS, it is not
what the patient
eats that causes
symptoms; rather,
the simple
act of eating
precipitates
bloating, gas,
and abdominal
discomfort”

are more likely to report constipationpredominant bowel habits, while men
are more likely to report diarrhea.9,10
Women are also more likely than men
to complain of bloating.
Symptoms usually begin in late
adolescence or early adult life, although
the problem may not be diagnosed
for years. The peak prevalence of
IBS occurs in the third and fourth
decades; the prevalence decreases in
the sixth and seventh decades of life.
Although IBS can be diagnosed at any
age, a new diagnosis of IBS should be
made cautiously in patients older than
60 because other diseases may present
with similar symptoms.
Besides the symptoms in the
Rome II criteria, patients with IBS
frequently suffer from straining,
bloating,
urgency,
feeling
of
incomplete evacuation and/or passage
of mucus during a bowel movement.
In many cases, patients with IBS also
complain of tiredness, breathlessness,
indigestion, heartburn, back pain,
headache, dizziness, urinary frequency,
muscle pains, arthritis, palpitations,
anorexia, sleeplessness, menorrhagia,
dyspareunia, panic attacks, anxiety
and depression.11
IBS can be associated with
significant emotional distress, poor
quality of life, disability and increased
health care costs. Patients with IBS
miss three times as many work days
as those without the disorder;12 in

Table 1
ROME II Criteria for Irritable Bowel Syndrome
Pain or discomfort for 12 weeks, which need not be consecutive, in the preceding 12 months,
associated with two of the following three features:
-

Relief with defecation

-

Change in stool frequency

-

Change in stool appearance or form

Symptoms that cumulatively lend support to the diagnosis:
-

Abnormal stool passage (straining, urgency or feeling of incomplete evacuation)

-

Passage of mucus

-

Bloating or feeling of abdominal distention
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fact, after the common cold, IBS is
the second leading cause of work
absenteeism.13 It is not uncommon
for IBS sufferers to limit their social
interactions, cancel appointments,
stop traveling, avoid sexual intercourse
and even stay confined to the house for
fear of embarrassment. Patients often
state that their symptoms dominate
their lives.
Pathophysiology
IBS is not caused by a single factor;
rather, it is a disorder in which a
number of physiologic processes are
involved. These include abnormalities
in intestinal motility, alterations in
visceral sensory function, changes
in central nervous system (CNS)
processing of sensory information, as
well as psychosocial and other factors.
Altered Gut Motility
Contractile
and
electrical
activities in the distal colon are
exaggerated in patients with IBS, and
can be demonstrated by increased
rectosigmoid contractile activity
in response to a meal, injections
of cholecystokinin, local infusion
of bile acids and distention of the
rectum.14 Several studies have shown
an abnormally high frequency of
discrete clusters of contractions in the
jejunum and prolonged propagated
contractions in the ileum,15 but these
findings are not specific for IBS.
Abnormal intestinal motility does not
seem to explain IBS in all patients, and
it is unclear whether it is a symptom or
cause of the disorder.
Enhanced Visceral
Sensitivity
Patients with IBS exhibit more
symptoms during transit of a standard
meal16 and during transit of gases17
than do normal subjects. There is also
greater sensitivity to rectal distention
at volumes lower than those that cause
pain in normal volunteers.18 The
observations that IBS patients are more
likely than controls to notice intestinal
contractions and gas are consistent with
the concept of enhanced perception of
visceral events. However, IBS patients
do not show somatic hypersensitivity
to pain and may have elevated somatic
pain thresholds.19

Post Infectious
There
is
well-documented
relationship between an attack
of gastroenteritis and subsequent
development of chronic symptoms
compatible with the diagnosis of
IBS. The precise mechanism for this
type of IBS is unknown; but several
possibilities exist. An infectious process
may transiently or permanently
injure the enteric nervous system; or
alternatively, an infectious agent may
initiate a cycle of chronic mucosal
inflammation that eventually alters
gut motility and/or sensation. Studies
have demonstrated that an increased
number of activated immune cells are
present within the intestinal mucosa
of patients with IBS.20 Post infectious
IBS patients tend to be women and
experience more severe acute illness.
Several studies have found that major,
sustained stressful live events occurring
either before or immediately following
the acute infection are the strongest
predictors of IBS development.21
Brain-Gut Interactions
The motor, sensory and secretory
activities of the intestines occur
through coordinated bidirectional
communications between the CNS,
ANS (autonomic nervous system),
and ENS (enteric nervous system),
forming what is known as the braingut axis.22 GI symptoms can result
not only from a disorder in the gut
itself but also from dysregulated
interactions at any level among these
control mechanisms of the gut.
Using
positron
emission
tomography scanning of the CNS
during rectal balloon distention,
Silverman et al23 demonstrated that
IBS patients had increased activity in
the prefrontal cortex (an area associated
with anxiety and hypervigilance),
and reduced activity in the anterior
cingulate cortex (an area important for
opioid binding), when compared to
healthy subjects. Another study that
used functional magnetic resonance
imaging also reported differences in
CNS activity in patients with IBS
relative to subjects without IBS.24 These
findings suggest that patients with IBS
may process sensory information from
the GI tract differently from patients
without IBS. In addition, other stimuli,

such as stress, anxiety, and depression,
may modulate sensory processing and
influence the perception of pain.
Role of Serotonin
Serotonin (5-hydroxytryptamine,
5-HT) is a naturally occurring
neurotransmitter
and
signaling
molecule. Ninety-five percent of
the body’s serotonin is found in
the gastrointestinal tract. Serotonin
appears to be the common link in GI
motility, intestinal secretion, and pain
perception and is involved at multiple
levels in the bidirectional interactions
between the ENS and the CNS. In the
GI tract, serotonin acts via intrinsic
ENS neurons to initiate motor and
secretory reflexes and via extrinsic
ENS neurons to initiate bowel-related
sensations such as pain and bloating.
As many as 14 serotonin-receptor
subtypes have been identified. Of
these, the 5-HT1p, 5-HT3 and 5-HT4
subtypes are considered the most
clinically relevant for lower GI-tract
function and regulation.25
Hormonal Factors
GI symptoms in women appear to
be influenced by female sex hormones,
increasing during the late luteal
phase and early menses. The effect
of menstruation on IBS symptoms
is thought to be mediated by ovarian
hormones affecting bowel function
either centrally or peripherally. This is
supported by the finding that during
pregnancy (state of high estrogen and
progesterone levels), GI symptoms
(nausea, constipation, upper GI
distress) increase2 and that IBS patients
on oral contraceptives that mimic
naturally fluctuating ovarian hormones
will continue to have amplification of
their GI symptoms during menses.26
In addition to a higher prevalence of
visceral pain in women patients during
the perimenstrual phase,9 the diagnosis
of IBS is threefold more common in
women with dysmenorrhea than in
those without.27
Food Intolerance
Although studies of dietary
restriction followed by the sequential
reintroduction of single foods have
suggested that food intolerance
exists in up to two thirds of patients
Vol. 88 No. 10 October 2005
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with IBS,28 true food allergies are
uncommon. Instead, in most cases of
IBS, it is not what the patient eats that
causes symptoms; rather, the simple
act of eating precipitates bloating,
gas, and abdominal discomfort. A
number of foods are known to cause
symptoms that can mimic or aggravate
IBS; e.g.,   dairy products, legumes
and cruciferous vegetables (broccoli,
cauliflower and cabbage), carbonated
beverages, caffeine, fatty foods,
alcohol, sorbitol and certain spices.
Psychosocial Factors
People with IBS who seek
medical help are more likely to
suffer from coexisting psychosocial
stress and dysfunction than those
who do not seek medical advice.29,30
Psychological disorders are frequently
seen concomitantly with IBS, but
probably do not  cause the symptoms.
Depression and anxiety are the most
common psychiatric conditions,
but phobias, obsessional behavior,
sleep disturbance, multiple somatic
symptoms, hostile feelings, panic
attacks, and alcohol abuse are also
more common than in healthy
control subjects.31 A history of major
life stress (sexual, physical or verbal
abuse, divorce or family death) plays
an important role in modulating
the illness experience and its clinical
outcome. Patients with IBS tend to
be more preoccupied with diseases
and tend to report more illness
not related to IBS. Female patients
with IBS are three times as likely to
undergo cholecystectomy, twice as
likely to have an appendectomy or
hysterectomy, and 50% more likely to
have back surgery.32 Such operations
may lead to scar pain, adhesions, and
further alteration in bowel habit.
Diagnosis
Evidence-based
consensus
recommendations developed by the
ACG Functional Gastrointestinal
Disorders (FGID) Task Force
advocate a stepwise, symptom-based
approach to the diagnosis of IBS.33
This approach involves identifying
the patient’s primary symptoms,
conducting a thorough patient history
and physical examination to exclude
signs suggestive of other diagnosis and
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making a decision about diagnostic
testing on the basis of the history and
physical examination. If alarm features
or “red flags” are present, such as severe
or nocturnal diarrhea, unintentional
weight loss, gastrointestinal bleeding,
anemia or family history of colon
cancer, directed diagnostic testing
should be performed to rule out the
possibility of organic disease.
Several intestinal disorders have
similar symptoms, such as lactose
intolerance, celiac sprue, inflammatory
bowel disease and microscopic colitis.
The danger of missing a diagnosis
needs to be balanced against the cost of
performing unnecessary investigations
and the risk of reinforcing illness
behavior. Many physicians are
concerned about diagnosing IBS
confidently without performing any
objective tests. A complete blood
cell count should be obtained, the
erythrocyte sedimentation rate (or Creactive protein level) and the thyroidstimulating hormone level measured.
If diarrhea is the patient’s primary
complaint, stool samples should be
tested. Serologic tests for celiac disease
can also be performed in patients
with persistent diarrhea. Flexible
sigmoidoscopy may be recommended
for younger patients with rectal
discomfort or bleeding. A colonoscopy
is warranted in patients who are 50
years of age or older, have a strong
family history of inflammatory bowel
disease or colorectal cancer, or show
evidence of anemia. In patients with
diarrhea, random colon biopsies can
be obtained to rule out microscopic
colitis.
Treatment
Although the cause of IBS is not
known and there is no cure, there are
several ways to manage this disorder,
according to the type and severity of
symptoms. The chronic nature of IBS
and the challenge of controlling its
symptoms can be frustrating for both
patients and doctors. An effective
physician-patient relationship plays an
important part of treatment. Patients
need to be educated and reassured
about their condition.
 	 The efficacy of drugs in IBS is
difficult to demonstrate due to the
high placebo response rate. The same

applies to dietary restrictions and
alternative medicine. Nonetheless,
such therapies should not be dismissed
simply because they have not been
verified in randomized controlled
trials. A symptom diary may help
pinpoint possible triggers and guide
treatment options. Any food that
appears to precipitate symptoms should
obviously be avoided. Increasing
dietary fiber (either by adding foods
to the diet or using fiber supplements)
can relieve constipation, but may also
help in diarrhea since it can improve
the consistency of stools. Dietary fiber
supplements should be increased to
the prescribed dose over several weeks
to reduce symptoms of excessive
intestinal gas. Gas-producing foods,
gum and carbonated drinks should
be avoided if the patients suffer from
bloating. Lactose intolerance is very
common in the general population,
and avoidance of dairy products may
be helpful in reducing symptoms of
IBS.
In patients with abdominal
pain, anticholinergic drugs, which
have antispasmodic effects, may
be prescribed to relieve severe
cramping. Drugs in this category
include dicyclomine (BentylR) and
hyoscyamine (LevsinR). Common sideeffects include dry mouth and eyes and
blurred vision. Antidepressants may
also be helpful due to a pain relieving
effect that is independent of their
depression relieving effect.34 Tricyclics
slow movement of contents through
the gastrointestinal tract and may be
most helpful in people with diarrheapredominant IBS. Selective serotonin
reuptake inhibitors can be prescribed
for IBS with constipation. Magnesium
hydroxide, lactulose or polyethylene
glycol solutions can also be prescribed
for constipation.   For diarrheapredominant IBS, antidiarrheal drugs
such as loperamide or diphenoxylate
with atropine can help slow bowel
transit time. These drugs should only
be used as needed, and rarely on a
continuous basis. Cholestyramine, a
bile acid binding agent, can also be
used for diarrhea in patients who have
undergone prior cholecystectomy.
Drugs affecting serotonin receptors
were developed for the treatment
of IBS. Women treated with the 5-

HT3 receptor antagonist alosetron
(lotronexR) experience significant
improvements in abdominal pain
and stool frequency and consistency
compared to placebo.35 After its initial
approval in 2000 by the US Food and
Drug Administration (FDA), the drug
was withdrawn from the market that
same year due to reports of ischemic
colitis. In response to patient and
public demand, the FDA reinstated
the drug in 2002 under restrictive
guidelines.
Phase III trials have demonstrated
the efficacy of cilansetron, another 5HT3 receptor antagonist, in women
and men with diarrhea-predominant
IBS.36 After the review process, the FDA
recently notified the manufacturing
company (Solvay Pharmaceuticals)
that further clinical trials are needed
before cilansetron can be approved.
Tegaserod (ZelnormR) is a partial
5-HT4 agonist. This drug accelerates
bowel transit37, relieving global IBS
symptoms, pain and constipation.
Although initially indicated only for
female IBS-C patients, it was also
recently shown to be effective for the
treatment of chronic constipation in
men and women and is also approved
for this indication.38 Headache and
diarrhea are the most commonly
reported adverse events. A recent
update on the safety of tegaserod was
issued by the manufacturer about rare
cases of ischemic colitis in the postmarketing use of this agent.
Non-pharmacological treatment,
such as massage, acupuncture, shiatsu,
meditation and hypnotherapy, can
be considered in IBS patients with
moderate to severe symptoms, when
patients have failed medical treatments,
or when there is evidence of stress or
psychological factors contributing to
symptom exacerbations.39
Conclusion
In the United States, up to 70%
persons with IBS symptoms do not
seek medical attention.40 Longitudinal
studies have shown that once IBS has
been diagnosed, nearly 75% of patients
will carry the diagnosis 5 years later.41
With a careful history and physical
examination, it is often possible for
the physician to make a positive
diagnosis of IBS. It is important in the
initial visit that psychosocial factors
that may contribute to symptoms are

elicited from the patient. It is also
important that patients receive an
adequate explanation about the nature
of their symptoms and the overall good
prognosis.   Although IBS can produce
substantial physical discomfort and
emotional distress, the vast majority
of patients learn to control their
symptoms.
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Update in Surgical Management of Female
Stress Urinary Incontinence
Vivian W. Sung, MD, and Deborah L. Myers, MD
It is estimated that the rate of
stress urinary incontinence (SUI) is
approximately 35% in older women
and 28% in younger women.1, 2  As life
expectancy among the US population
increases, the prevalence of this disorder will increase.  It is predicted that
by year 2030, the number of women
over age 55 will almost double to over
60 million.3   The predicted shift in
demographic makeup of the United
States and improved overall health will
lead to an increase in the number of
women receiving care for SUI.4  
Although rarely life threatening,
SUI may precipitate insecurity, embarrassment, depression, social disengagement, and/or   psychological and
functional decline.   Spousal relationships can be negatively affected and
women with urinary incontinence
may have poorer sexual functioning.5  
In 1995, the annual direct cost of urinary incontinence in the United States
was estimated at $16.3 billion; the
majority of these costs went to routine
care including laundry and protective
garments (70%).6  Only 1-3% of these
costs were attributed to diagnosis and
treatment of the disorder.  
In the past urinary incontinence
was considered to be a natural, and
unavoidable, result of aging.  Despite
treatments, it is estimated that only
13% of women will seek help for this
condition.7  Some women, with mild
symptoms do not feel that treatment
is needed.  Other women are embarrassed to speak with a health care
provider about the condition; some
women may believe the only treatment is major surgery.  Finally, physicians may not feel prepared to discuss
treatment options with their patients.    
The Agency of Heath Care Policy and
Research estimated that only 20% of
physicians routinely discussed urinary
incontinence with patients and most
physicians felt inadequately prepared
to discuss options.8   As minimally
invasive surgical treatments evolve,
women who were once considered
non-surgical candidates have increased
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options.  This article will review diagnosis, management and surgical treatment options for SUI.
Diagnosis
The International Continence Society defines SUI symptoms as “involuntary leakage on effort or exertion, or
on sneezing or coughing, in an amount
unacceptable to the patient.”  SUI can
be evaluated and treated at many levels, depending on how bothersome
the symptoms are to the patient.  It is
possible to reach a working diagnosis
of SUI based on symptoms alone and
the clinician may initiate conservative,
non-surgical treatment.  Women who
have a satisfactory response may not
need further testing.
Women who do not respond to
conservative therapy will need a more
detailed evaluation.  A detailed history

“It is estimated
that the rate of
stress urinary
incontinence is
approximately
35% in older
women and 28% in
younger women.”
includes questions about frequency
and amount of leakage, precipitating
factors, impact of leakage on daily
life and pad use pelvic organ prolapse
symptoms, urinary urgency, nocturia,
incomplete bladder emptying, hematuria, and anal incontinence.   A detailed pelvic examination assesses neurologic function, pelvic organ support,
and pelvic muscle strength.  A cough
stress test will help confirm the diagnosis.   A postvoid residual will help
rule out urinary retention. A urinalysis
and culture will help rule out urinary
tract infection.
Further assessment of bladder
function with urodynamic testing is

recommended for women with an
unclear diagnosis, women considering
surgical treatment, women with an elevated postvoid residual volume or a
neurologic condition, significant pelvic organ prolapse, or prior attempts
at surgical correction.   Urodynamic
testing provides a more precise evaluation and includes a combination of
tests measuring urethral and bladder
function during bladder filling, storage, and emptying.  
Treatment
The treatment goal for SUI is
achieving a cure or minimizing the
impact of the condition.  Once the diagnosis of stress incontinence is made,
a treatment strategy will consider the
severity of symptoms, degree of bother,
associated pelvic floor conditions, prior surgery, and a patient’s willingness
to accept the risks and success rates of
different interventions. Many women
report satisfaction even if they are
not completely dry.9, 10   Conservative
options should always be discussed.
These include behavioral modification (fluid intake modification, weight
loss for obese patients), pelvic floor
exercises with or without biofeedback,
and vaginal supportive devices.  Pharmacologic therapy includes tricyclic
antidepressants (imipramine) which
facilitate bladder storage and increase
urethral resistance.   Duloxetine, a serotonin and norepinephrine reuptake
inhibitor, is being investigated in the
treatment of SUI.11
Patients who are dissatisfied with
conservative measures may opt for
surgical treatment.   The choice of
procedure is guided in part by severity
of SUI, presence of associated pelvic
prolapse, voiding function, patient comorbidities and patient preference.

Retropubic Colposuspensions (MMK or
Burch)
The basic goal of retropubic suspensions is to suspend the anterior vagina and stabilize the bladder neck in a
retropubic position, allowing urethral

compression against a stable suburethral support.   Trans-abdominal retropubic suspensions involve entering
the retropubic space, placing sutures
in the periurethral fascia and suspension to nearby structures including
the periosteum of the pubic bone or
Cooper’s ligament.12-15
In 1997, members of a clinical
guidelines panel from the American
Urological Association reviewed the
literature and outcomes data on surgical treatment of female SUI.16  The
panel concluded that retropubic colposuspensions were effective in the
treatment of SUI, with median cure
rates of 84% (95% CI 79-88%) at 2
years or greater.   Postoperative complications of retropubic procedures
include voiding dysfunction (10%),
prolonged urinary retention (5%), de
novo detrusor overactivity (17%), and
risk of future enterocele (7-13%).17-19  
A laparoscopic approach may
also be used to perform the Burch
colposuspension.   Advantages of the
laparoscopic approach include smaller
skin incisions, quicker post-operative
recovery and return to work.   Disadvantages may include longer operative
times, especially during the surgeon
training period, and technical difficulty.  
There is little level 1 evidence
comparing the laparoscopic approach
with the traditional abdominal approach.   In 2004, the Cochrane Incontinence Group reviewed 8 randomized trials and concluded that the
cure rate for laparoscopic colposuspension trended lower compared to
the open approach (relative risk 0.91;
95% CI 0.82-1.01).20   However, different techniques and modifications
to overcome laparoscopic suturing,
and inconsistent numbers of sutures
were used between studies, making
comparisons difficult and unreliable.  
The long-term success of laparoscopic
colposuspension remains unclear and
well-designed randomized trials are
required to definitively compare these
procedures.
Bladder Neck Slings
Suburethral slings are designed to
support the bladder neck and urethra.  
The sling forms a “backboard” to support the urethra while providing a
mild component of urethral compres-

sion.  Due to increased dissection and
concern of denervation with traditional slings, these procedures were often
reserved for women with recurrent
incontinence or intrinsic sphincter deficiency.  The American Urological Association determined in 1997 that the
sling procedure was an effective treatment for SUI.  Median success rate for
sling procedures were comparable to
retropubic colposuspensions and estimated to be 83% (95% CI 75-88%)
at 2 years or greater.
Numerous materials are available
for suburethral slings.  Autologous rectus fascia and fascia lata are commonly
used and require either an abdominal  
or leg incision to harvest the fascia.  
There are also a variety of synthetic
materials including Gore-Tex, prolene,
and Mersilene.   Comparative studies
of ideal sling materials are lacking.
Similar to retropubic colposuspensions, bladder neck slings have a
risk of voiding dysfunction of 12.8%,
prolonged urinary retention of 8%,
and de novo urge symptoms of 7%.
The Urinary Incontinence Treatment
Network, a National Institutes of
Health-sponsored network including
9 centers, is comparing long-term (24
months) outcomes following Burch
colposuspensions and autologous rectus fascia slings in a randomized trial.
Midurethral Slings
Tension free vaginal tape
sling (TVT):
The search for more minimally
invasive sling procedures led to the
evolution of the TVT™ (Gynecare,
Sommerville, NJ) sling.   The TVT
aims to restore continence through
compensation of the pubourethral
ligaments and formation of a firm
backboard for the urethral to close
against during episodes of increased
intra-abdominal pressure.21  The TVT
is tension-free, which differs from traditional bladder neck slings that have
an obstructive component.
The TVT was introduced in the
1990s; initial success rates were reported through case series from individual institutions. Ulmsten, et al
reported that at 2-3 years following
the TVT, 86% of women were dry, an
additional 13% were improved, and
3% had no improvement.22  Nilsson,

et al reported five-year subjective and
objective cure rates as 84.7% cure rate,
10.6% improvement rate, and a low
4.5% failure rate.23
The TVT may be performed
under local or minimal regional anesthesia and is often performed on
an outpatient or overnight stay basis.  
Operative time is short and in general,
postoperative pain and recovery are less
severe than traditional slings and retropubic colposuspensions.  Two small
0.5-cm suprapubic skin incisions are
made, and one 1.5 cm incision is made
in the vagina over the midurethra.  A
thin strip of polypropylene mesh tape
is then passed vaginally through the
suprapubic incision on either side with
4-mm needles and the mesh is situated at the midurethra, tension free.  
There is no need to suture the mesh in
place.  Variations of the TVT include
the SPARC ™ (American Medical
Systems, Minnetonka, Minn), a “topdown” method of passing the needles.  
Complication rates are overall
favorable following the TVT.   The
risk of prolonged urinary retention is
2%, retropubic hematoma is 1.9%, de
novo urinary urgency is 5%, and sling
erosion is low, <1%.24, 25   The most
common intraoperative complication
is bladder perforation (3.6%), but
long-term sequela following this event
are rare.   Although rare, there are reports of injury to bowel, iliac vessels
and the obturator nerve.
In 2004, Ward and Hilton published results from a large, multi-center randomized trial comparing the
TVT to the open Burch colposuspension.26  At 2 years, the authors found
no difference in success rates between
the two procedures.   Depending on
how missing data was treated, objective cure ranged from 63-85% for the
TVT group and 51-87% for the colposuspension group.   Women in the
TVT group were less likely to have
voiding dysfunction requiring self
catherization and had shorter recovery
times.
Trans-obturator tape
(TOT)
Given the rare but potentially
serious complications with the TVT,
there has been a search for a safer but
equally effective alternative.  The TOT
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was first described in 1998; based on
early case series, the clinical effectiveness was similar to the TVT.   The
TOT is also a midurethral sling, thus
the same principles and mechanisms
of the TVT apply.  A small incision is
made at each groin and a 1.5 cm vaginal incision is made in the anterior vagina over the midurethra.  A thin strip
of prolene mesh tape is placed under
the midurethra which then passes behind the ischiopubic ramus, punctures
the obturator membrane and passes
through each corresponding groin incision.   
Like the TVT, the TOT is often performed under local or light
regional anesthesia on an outpatient
basis.   Operative time is short, and
patients recover quickly.   A proposed
advantage of the TOT is a decreased
risk of bleeding, as there are no needles
passed through the retropubic space
and the great vessels are not at risk.  
This also theoretically decreases or
eliminates the risk of bowel and bladder injury, although there has been a
report of bladder perforation with this
approach.27  Another proposed advantage is lower risk of urinary retention
and voiding dysfunction, due to less
risk of over-correction.  
The greatest risk with this approach may be injury to the obturator
nerve and vessels.   In cadaver studies, the obturator nerve branches and
bundle are on average 2.5-cm from
the mesh.28  The most medial obturator vessel is on average 1.1-cm from

the mesh.  The risk of obturator nerve
injury with this approach is likely low,
and consequences of injury to obturator vessels are unknown.  Based on a
query of the MAUDE database, (an
FDA database that collects physician
initiated reports of complications associated with medical devices), the complication rate associated with the TOT
is 0.0001%.29   However, this physician-initiated database likely underestimates the true complication rate.  
 	 There is very limited data comparing efficacy rates of the TOT with
traditional bladder neck slings or the
TVT.  Based on one small randomized
trial, the TOT approach is associated
with a significantly shorter operative
time compared to the TVT (approximately 15 vs. 30 minutes).30  However, this study was not powered to compare efficacy rates.  Although the TOT
appears promising, benefits, cure rates,
management of nerve and vessel injury remain unclear.  The TOT may be
reserved for cases where the retropubic
space should be avoided (ie: women
with prior retropubic surgery, history
of retropubic bleed, history of reconstructive abdominoplasty).   Well-designed, controlled and comparative
studies are still needed before this approach is routinely used.
Urethral Bulking Agents
The goal of bulking agents in the
urethra is to improve urethral coaptation during the storage phase and to
maintain coaptation during episodes

Table 1
Diagnosis and Evaluation of Urinary Incontinence
History
•
Identify symptoms and severity
•
Impact on quality of life, degree of bother
•
Rule out chronic illnesses that may affect fluid balance
•
Review medications with possible adverse urinary effects (eg, anticholinergics, diuretics, antidepressants, antipsychotics, alpha-blockers)
•
Review prior pelvic surgeries
Physical Examination
•
Assess neurologic function
•
Assess pelvic organ support
•
Cough stress test or objective demonstration of stress incontinence
•
Post void residual to rule out retention
•
Urinalysis and culture to rule out infection
Urodynamic studies*
•
Confirm stress incontinence
•
Assess for urge urinary incontinence
•
Assess bladder compliance
___________________________________________
*Not required.
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of increased intra-abdominal pressure.  
Bulking agents may be administered
under local anesthesia as an outpatient
procedure or performed in the office.  
The agents may be injected at the
bladder neck using a periurethral or a
transurethral approach.  
Agents include glutaraldehyde
cross-linked collagen, a highly purified suspension of bovine collagen
(GAX™, CR Bard, GA).   The implant does not cause any inflammatory
reaction, but does degrade over time.  
All patients must undergo skin testing
with collagen before the procedure to
confirm that they are not sensitized to
collagen, which may occur through dietary exposure.  
Carbon beads are composed of
non-absorbable pyrolytic carboncoated zirconium oxide beads (Durasphere ®; Boston Scientific, Natick,
MA).  Although in theory this agent is
permanent and not biodegraded, cure
rates have not been shown to be improved compared to collagen.31  There
have also been reports of migration of
the agent.
The Food and Drug Administration (FDA) recently approved
ethylene vinyl alcohol (Tegress ™,
CR Bard) for transurethral injection.  
At body temperature, the polymer
precipitates into a spongiform, nonabsorbable mass; skin testing is not
needed.
Other agents include silicone micro-particles, polytetrafluourethylene
paste, calcium hydroxyl apatite, and
autologous fat. Overall, bulking agents
have a wide range of success rates, from
13%-78%.32  Many women may need
multiple injections to reach acceptable
improvement.  Long-term success and
durability are the primary concerns
with bulking agents.  However, these
procedures are very low risk and may
be offered to women with multiple comorbidities, or women who are poor
surgical candidates.
Conclusion
SUI is a common condition, and
minimally invasive procedures may
improve a woman’s symptoms and
quality of life.  As the population ages,
it will be important for health care
providers to be familiar with the treatment options.

Table 2
Treatment Options for Stress Urinary Incontinence
Absorbent products
Behavioral therapy/Pelvic floor rehabilitation
Continuous catheterization
Occlusive devices
Pharmacologic therapy
Alpha-adrenergic agonists
Serotonin-norepinephrine reuptake inhibitors
Surgical treatment
Retropubic colposuspension
Bladder neck sling
Mid-urethral sling
Urethral bulking agents
____________________________________________
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Obesity in Women
Suzanne Phelan, PhD, and Rena R. Wing, PhD
Obesity rates are reaching
epidemic proportions in the United
States and other industrialized nations.  
In the United States, 34.1% of the
population is overweight (defined as a
BMI of 25-29.9 kg/m2), while 31.1%
are obese (BMI> 30 kg/m2).  Obesity
affects 34.0% of women and 28.1%
of men.  Non-Hispanic black women
have the highest rates of obesity: nearly
half are obese. (Table 1)   Obesity
is six times more prevalent among
women of low as compared with high
socioeconomic status.
Obesity causes, exacerbates, and
predisposes to many diseases affecting
women, including heart disease, breast
and endometrial cancers, diabetes,
urinary incontinence, and arthritis.1  
Weight gain in women during adult
life is associated with increased risk of
heart disease and death.1, 2 Even modest
weight gains after age 18 dramatically
increase the risk for the development
of diabetes.2, 3  
Fortunately, modest weight
losses of 5%-10% of body weight
are sufficient to control, or at least
improve, most complications of obesity.   
Improvements in blood pressure, serum
triglycerides, high-density lipoproteincholesterol, low-density lipoproteincholesterol, blood glucose levels,
sleep apnea, osteoarthritis, and gout
are observed.   In a recent large-scale
study, increased physical activity and
loss of 7 kg prevented or delayed the
onset of type 2 diabetes in individuals
with impaired glucose tolerance.  
Participants who were assigned to
lifestyle intervention reduced their risk
of developing type 2 diabetes by 58%.  
Participants receiving standard care
plus pharmacotherapy (metformin)
reduced their risk of type 2 diabetes by
31%: lifestyle intervention was twice
as effective as medication.  
Key Components of
Successful Weight
Control
Much of what we know about
lifestyle change to promote successful
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weight loss is derived from the National
Weight Control Registry (NWCR)
data.   The NWCR is a registry of
individuals who have successfully
maintained a loss of at least 13.6 kg
for at least 1 year.4   However, the
5,000 participants in the NWCR have
far exceeded these minimum criteria;
on average, they have lost almost 70
lb and kept it off for 6 years.  Research
from the NWCR and randomized
controlled trials have identified several
key lifestyle changes for long-term
successful weight control.   (Table 2)  
These include consumption of a low
calorie, low fat diet, engaging in high

“… modest weight
losses of 5% -10%
of body weight
are sufficient
to control,
or at least
improve, most
complications of
obesity.”
levels of physical activity, and selfmonitoring.  
Consumption of a low calorie, low
fat diet.  Although the optimal degree
of caloric restriction remains unclear,
typically diets of approximately 1200-

1500 kcal/day for women and 15001800 for men are recommended, with
fat intake <30% of calories.   Data
from the NWCR support these low
calorie, low fat recommendations.  In
addition, 78% of registry members
reported eating breakfast every day of
the week.   Maintaining consistency
in the diet also appears to be a key
characteristic of NWCR participants;
most participants reported that their
eating was the same on weekends and
weekdays and on holidays/vacations
and the rest of the year.
Recently, there has been renewed
interest in diets that severely restrict
carbohydrate intake, like the Atkins’
and South Beach diets.   Such diets
are only beginning to be formally
evaluated in weight loss trials.  
Short-term evaluations have found
significantly greater weight losses
with low carbohydrate regimens
relative to low fat, low calorie
regimens.  Two long-term evaluations
of low carbohydrate diets found no
significant differences relative to lowfat diet controls at 1 year.5, 6  Although
low-carbohydrate dieters are often
allowed to eat as much protein and fat
as they desire, the average intake on
these regimens is approximately 1500
kcal/day; this reduced calorie intake is
responsible for the weight loss seen on
these regimens.  
Self-monitoring of body weight,
food intake, and physical activity.   Self-

Table 1. Proportion of Women Overweight or Obese
(Females aged 20 to 74 years by race and Hispanic origin, 1999–2002)
Race/Ethnicity

Overweight
(BMI greater than
or equal to 25)

Obese
(BMI greater than or
equal to 30)

White
(non-Hispanic)

57.0%

31.3%

African American/
Black (non-Hispanic)

77.5%

49.6%

Mexican American

71.4%

38.9%

Age adjusted to the U.S. year 2002 standard population.
Source: Centers for Disease Control and Prevention, National Center for Health
Statistics, National Health and Nutrition Examination Survey, Health, United
States, 2002.

Table 2. Key Strategies for Long Term Successful Weight Loss
Consume a low calorie diet

1200-1500 kcal/day for women
1500-1800 kcal/day for men

Consume a low fat diet
Consume breakfast
Increase physical activity

<30% kcal/day from fat
Eat breakfast daily
Goal of 60 minutes/day

Self-monitor weight, intake, and
exercise

Record daily

monitoring appears to be another
important ongoing strategy for
successful weight loss.   Seventy-five
percent of members in the NWCR
weighed themselves at least once per
week, and 44% weighed themselves
daily.   Additionally, 50% of registry
members reported that they still
occasionally counted calories, fat grams,
or both. Other treatment studies have
confirmed the role of self-monitoring
in successful weight management.  
Notably, self-monitoring is often not
totally accurate; in fact, estimates of
dietary intake obtained from such
recording underestimate actual intake
by 30% on average.   Therefore, this
technique should be viewed more
as a behavior change tool than as an
assessment technique.
Engaging in High Levels of Physical
Activity.  Correlational studies, as well

as controlled trials, show consistently
that persons who engage in regular
physical activity are the ones most
likely to maintain a reduced weight.  
Almost all participants (91%) in the
NWCR reported engaging in regular
physical activity. On average, women
in the registry reported that they
engaged in 2545 kcal/week of physical
activity and men engaged in an average
of 3293 kcal/week in physical activity.  
This amount of physical activity is
comparable to walking about 28
miles/week or about an hour per day
of moderate intensity physical activity.  
This amount of physical activity is
also consistent with the United States
Department of Agriculture’s (USDA)
recommendations for the general
public.  The USDA recommends that
adults engage in 60 to 90 minutes/day
of moderate intensity physical activity

“Learn from fellow physicians in Rhode Island how to successfully redesign your
approach to diabetes in a way that promotes patient and doctor satisfaction while
earning financial incentives for your practice”…
Chris Campanile MD, PhD
Chairperson, RI Chronic Care Collaborative
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Mark Schwager, MD
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to sustain weight loss in adulthood.  
Most NWCR subjects meet this
recommendation.  
Results of other studies support
the recommendation for high levels of
physical activity and suggest that high
levels may be necessary to prevent
weight regain after weight loss.  Jakicic
et al.8 reported that greater levels of
physical activity had minimal impact
on 6-mo weight loss in women
who were reducing energy intake.
However, the higher amounts of
exercise appeared to be more effective
for prevention of weight regain. It
was reported that women engaging
in ~280 min/wk of at least moderate
intensity physical activity (i.e., brisk
walking) throughout the 18-mo study
reduced their body weight by 13 ± 8.0
kg, whereas exercising <200 min/wk
or <150 min/wk resulted in weight
loss of 8.5 ± 5.8 and 3.5 ± 6.5 kg,
respectively.
Dividing physical activity into
multiple 10-min bouts may facilitate
initial adoption of activity in previously
sedentary women.   Home-based
exercise programs and the use of home
exercise equipment may also enhance
exercise adherence and improve the
maintenance of weight loss.  
Treatments Specific for
Women
Several treatments have been
tailored to address weight concerns
of women.   Although the basic
elements of treatment are consistent
with standard weight control practices
(i.e., modifying diet, physical activity,
and self-monitoring), the timing and
structure of treatment may be tailored
to address the needs of women.
Pregnancy One period when
obesity prevention efforts may be
particularly effective for women is
the period surrounding pregnancy.  
Although studies of the general
population have reported average
weight gains of only 0.4 to 3.8 kg more
than aging, approximately 25% of
women experience a weight gain of 4.5
kg or more with pregnancy.  Moreover,
weight changes during pregnancy are
strongly related to subsequent weight
change and future obesity.   
Vol. 88 No. 10 October 2005
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The single strongest predictor
of weight gain from pre-to 1-year
post-pregnancy is the magnitude of
weight gained during pregnancy. The
National Academy of Science Institute
of Medicine (IOM) has formulated
recommendations for healthy weight
gain during pregnancy.   However, in
a recent study of 500 pregnancies in
Rhode Island, we found that more
than one-third of normal weight
women and two thirds of overweight
women exceeded these recommended
levels; similar findings have been
observed elsewhere.9, 10  
Women with excessive weight
gains during pregnancy are at
increased risk of retaining significant
degrees of weight postpartum.11  
Moreover, weight gains that exceed
the recommended levels have been
connected to hypertension, diabetes,
pre-eclampsia, cesarean sections, and
babies that are large for gestational age.  
Helping women gain the recommended
amount during pregnancy through
healthy eating, physical activity,
and self-monitoring, could prevent
excessive weight retention and its
associated complications.   The years
preceding and/or following pregnancy
may provide other opportunities
(“teachable moments”) for practitioners
to help women achieve and maintain
a healthy body weight. Breastfeeding
for one-year post-partum may slightly
reduce one-year weight retention, but
has other benefits for maternal and
infant health.    Our clinic is seeking
to determine whether the incidence of
pregnancy-associated weight retention
and obesity can be reduced through
behavioral lifestyle interventions that
target the pre-pregnancy, pregnancy,
and/or the postpartum periods.
Menopause   Another high-risk
time for weight gain in women is the
period surrounding menopause. In a
longitudinal study of 541 healthy premenopausal women, aged 42 – 50 at
study entry, the average weight gain was
5 pounds over 3 years and 12 pounds
over 8 years. This gain was associated
primarily with aging, rather than with the
hormonal changes of menopause per se.
Moreover, decreased physical activity
was the most consistent behavioral
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factor associated with this gain.
The
menopausal
transition
is associated with a worsening in
cholesterol levels, an effect which is
particularly pronounced in women
who gain weight at this time.
Therefore,
lifestyle
intervention
aimed at modifying dietary and
physical activity behaviors might help
prevent both the weight gain and
the worsening in cardiovascular risk
factors. The Women’s Healthy Lifestyle
Project 12 was a 5-year randomized
clinical trial testing the hypothesis
that lifestyle intervention could
reduce the magnitude of weight gain
and the increase in LDL-cholesterol
seen in women during the time of the
menopause.  The 535 participants were
aged 44 – 50, had a BMI of 20 – 34,
fasting cholesterol of 140 – 260 mg/
dl and a fasting LDL-C of 80 – 160
mg/dl. These women were randomly
assigned to lifestyle intervention or an
assessment only control group.
All women, including those who
were normal weight, were encouraged
to lose weight initially to offset the
anticipated weight gain.   Women
who were normal weight (BMI < 24
mg/dl) were encouraged to lose 5 lbs;
those with a BMI of 25 – 26 were
encouraged to lose 10 lbs; those with
a BMI of 27 – 34 were encouraged
to lose 15 lbs. Women consumed a
low calorie/low fat diet and increased
physical activity to a goal of 1000 –
1500 kcal/week. Intervention activities
included 6 months of group meetings
followed by periodic individual and
group sessions throughout the 4 years.
Follow-up assessments were held at 6,
18, 30, 42, and 54 months.
The intervention was effective
in blunting the anticipated gain; the
intervention group lost 10.8 lb during
the first 6 months. Although these
women gradually regained weight over
the course of the trial, they maintained
a weight loss of    -0.2 lb at 54 months.  
This contrasted with a 5.2 lb weight
gain in the control group.  At the end
of the study, 55% of the intervention
participants were at or below their
baseline weight, compared with 26%
of controls (p < .001). Weight loss was
strongly associated with adherence to

both physical activity and the dietary
prescriptions.
The intervention also produced
significant effects on   lipids, blood
pressure, insulin, and glucose. At
month 54, LDL cholesterol in the
intervention group had increased by
3.5 mg/dl, whereas the control group
had increased by 8.9 mg/dl (p .009).
Waist circumference decreased 2.9 cm
in the intervention group compared
with .5 cm in the control. Thus,
intervention at this time period may
have multiple benefits for women.
Urinary incontinence    Urinary
incontinence may be alleviated by
weight loss. An estimated 13+ million
women in the US have urinary
incontinence; including approximately
25% of reproductive age women and
50% of postmenopausal women.
Epidemiological studies show that
obesity is a strong risk factor for
incontinence; each 5-unit increase
in BMI leads to 60% increase in risk
of daily incontinence. Among older
women with incontinence, 65 – 75%
are overweight.
Several studies have suggested that
weight loss may improve incontinence.
Subak et. al13 reported results of a small
randomized trial with 42 overweight
or obese incontinent women: 22
were randomized to an immediate
weight loss condition, 20 to a delayed
treatment control. The weight loss
intervention included a very low
calorie diet, exercise, and behavior
modification.  The intervention-group
women lost 14 kg compared to a 0 kg
in the control group.  This weight loss
resulted in a 60% reduction in weekly
incontinence episodes compared to a
15% reduction in the control group.  
In the intervention group, 16% of
women had 100% improvement in
incontinence, 37% were at least 75%
improved, and 58% were at least 50%
improved. Stress and urge incontinence
both decreased in the treatment group
vs. the wait-list.
The NIH (NIDDK) recently
funded a multi-center clinical trial,
PRIDE (Program to Reduce
Incontinence through Diet and
Exercise), testing the effectiveness of
weight loss for women with urinary

Table 3.
NIH-funded Studies Currently Recruiting at the
Weight Control and Diabetes Research Center (401-793-8940)

9.

PRIDE: Program to Reduce Urinary Incontinence by Diet and Exercise.
This study provides an 18-month weight loss program for overweight
women aged >30 years with > 10 incontinent episodes/week.
LEAP: Lifestyle, Eating and Activity Program. This 18-month program is
recruiting pairs of overweight individuals who live together (e.g., spouses)
to examine the effects of modifying the home environment.
LITE: Living Lean in a Toxic Environment. Individuals who are normal
weight or have successfully reduced from obese to normal weight are
provided information about their current eating and exercise habits.
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Center, The Miriam Hospital, are
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Warwick, RI 02889
this trial. A total of 165 women will
be studied at The Miriam Hospital.
(Table 3)  
f 739-7671
Concerns about Weight
Loss in Women
In the past, dieting was criticized
for limited effectiveness, causing
adverse emotional responses or
precipitating binge eating.   However,
recent studies and a review by the
National Task Force on the Prevention
and Treatment have put these concerns
to rest.   The review concluded that
dieting in overweight and obese
women is not associated with adverse
psychosocial or behavioral effects.  On
the contrary, dieting and weight loss are
associated with numerous psychosocial
and physical benefits.   In particular,
weight loss regimens including very
low calorie diets have not been shown
to increase binge eating.
Dietary-induced weight
loss
may result in a loss of bone mass in
overweight women.  In a randomized
study, women in the weight loss
intervention who lost 3.2 kg over 18
months experienced a 2-fold increase
in rate of hip bone mineral density
(BMD) loss compared to the control
group, which gained 1.5 kg.14   A
similar pattern was seen for BMD
change at the spine, although the
difference was non-significant.  Large
increases in physical activity helped
reduce the amount of spine BMD loss,
but not hip loss.   Since osteoporosis
is an important health concern for
women, further research is needed to

Conclusion
Obesity affects the health of
millions of women nationwide.  
Successful weight loss typically involves
a combination of consuming a low
calorie, low fat diet, engaging in high
levels of physical activity, and frequent
self-monitoring.   Promoting such
lifestyle changes during critical life
junctures for women, such as during
pregnancy and menopause, may be
effective in treating and preventing
obesity-related diseases in women.
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A 20 cm Mass in a 28 Year-old Woman
Beth Plante, MD, and Troilus Plante, MD

Image 2: Ultrasound image of the same simple-appearing cystic mass
Image 1: CT scan revealing a 20 x 17 x 8 cm cystic lesion
emanating from the right ovary

A 28-year-old woman presented with one month of
abdominal pain.  The CT scan and ultrasound images
displayed are consistent with a large simple-appearing
cystic structure in the abdomen and pelvis measuring 20
x 17 x 8 cm, arising from the right ovary.  The CT scan
revealed no free fluid, lymphadenopathy, or suspicious
lesions in the abdomen and pelvis.  The ultrasound characteristics were highly suggestive of a benign process.  
The mass had no malignant features, such as internal
septations, solid components, papillary projections, or
internal echoes.  The literature suggests that the sensitivity of transvaginal ultrasound for the detection of a
malignant adnexal mass ranges from 85 to 97%, and the
specificity varies between 56 and 95%.  The sensitivity
and specificity may improve when color Doppler is used
in addition to standard morphologic analysis with transvaginal ultrasound.  In light of the patient’s age and reassuring radiographic findings, it was felt that there was
a very high likelihood that the mass was benign.  This
patient underwent a CT-guided drainage of the cyst to
facilitate a laparoscopic surgical resection.  Approximately 1400 cc of straw-colored fluid was obtained.  Intraoperatively, the patient was found to have a large collapsed
right ovarian cyst with no evidence of ovarian torsion.  
The cyst wall was excised laparoscopically.  Final pathology was consistent with a benign serous cystadenoma.  
Serous tumors, including benign, borderline, and malignant subtypes, account for approximately 30% of all
ovarian tumors.  
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Image 3: Laparoscopic image of the collapsed cyst wall after drainage
of 1400cc of straw-colored fluid from this benign serous
cystadenoma
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Creative Clinician Case
FUTURE OF BREAST SURGERY
Jennifer S. Gass, MD, FACS
A 57 year old woman presents to
your office with a 1.2 cm moderately
differentiated infiltrating ductal carcinoma, highly ER/PR positive, detected on screening mammography and
biopsied under ultrasound guidance
with good correlation of size.  She has
a clinically negative axilla and no significant medical co-morbities.   After
presentation at a prospective multidisciplinary tumor board, consensus recommendation is for needle localized
wide local excision and sentinel node
biopsy - the textbook response. Yet
could there be a better approach?
The Evolution of Breast
Surgery
The universe is in a constant state
of flux.  Medicine like nature advances
through what sometimes feels like
a random process of evolution, and
while when evaluated in short-term
segments it can seem unclear whether
true advances are made, over centuries
it seems certain that we do.  In breast
cancer therapy, a similar process governs change.  Looking back to the first
recognized pioneer in breast cancer
therapy William Halsted, who developed the first standardized approach;
radical resection of the breast, chest
wall and nodal basins, it is easy to see

Figure 1 A. Ultrasound demonstrating
Cryoprobe placement within target
lesion.

how far we have come.   In Halsted’s
era, it was uncontrolled local disease
that ravaged the patient and seemed to
cause death. With the diagnosis of early staged, surgically controllable disease, Fisher and colleagues turned the
world’s attention to addressing distant
failure; ushering in the era of systemic
chemotherapy. The seminal NSABP
B-04 and B-06 trials have reached
maturity with over 20 years of followup still showing no survival difference
between breast conservation and more
radical resection.   Venturing even
further into therapeutic minimalism,
surgeons have practically abandoned
axillary dissection in favor of sentinel
node biopsy for the clinically negative
axilla.  The more precise surgical intervention is permitted by an earlier diagnosed breast cancer, afforded by the
standardized screening of women over
fifty years of age since the 1978 NIH
recommendation.1   Since that time
we have seen a progressive decrease
in breast cancer size, with the mean
diameter of breast cancer decreasing
by 10% every five years. For Rhode
Island, with the most successful statewide mammographic screening program, the median size of breast cancer
has decreased from 2.0 cm in 1987 to
1.5 cm in 2001.  As cancers are identi-

fied below the limits of tactile discretion; excision guided by palpation is
replaced by image-directed surgery.  
Yet the standard approach of excision
remains.  Is this the best we have to offer?  Or is there, in the current milieu
of minimal invasive-ism, an opportunity to revolutionize the approach to
breast cancer surgery.
Contemporary Strategies
The goals of breast cancer surgery are to surgically remove the index
cancer from the body, eliminating its
potential for future metastasis. and
to stage the axilla.  Subsequent radiotherapy completes the local control.  
While excising the cancer is way to
achieve this endpoint, other options
are numerous.   While more contemporary modalities in-situ ablation were
not available, Hippocrates described
the concept of thermal destruction
as 460 BC and in the first century
another Greek physician, Leonides,
described a process of incision and
cauterization.  Alas what is old is new
again, this time centuries later.  Contemporary literature is replete with reports of the successful use of thermal
ablation of lung, liver, bone, adrenal,
kidney, and prostate in both the metastatic and primary settings.  Advances

B. Ultrasound during creation of iceball. Note clear delineation of treatment field.
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(Figure 2) The entire prohave extended this therapeutic option
to other tumor sites, including breast
cancer.
The initial reports of ablative
techniques in breast cancer therapy
focused on radiofrequency ablation.  
However, this technique suffered from
two serious flaws.  First, thermal heating is associated with intense discomfort and secondly with RFA under
ultrasound guidance, visualization of
the treatment zone is severely compromised.   Although other modalities such as focused microwave, laser
and ultrasound ablation have been
described, the remaining literature focuses on cryoablation.  Cryoablation is
ideally suited to breast cancer therapy
for many reasons.  First, the majority
of invasive breast cancers found today
are identified by mammography but
characterized and biopsied under ultrasound guidance.  The small powerful hand-held ultrasound probe makes
ultrasound the ideal modality to guide
of breast therapeutic interventions as
well.   Furthermore, during cryoablation, frozen tissue becomes imminently visible under ultrasound, in direct
contradistinction to thermally heated
tissue (Figure 1A,B). Additionally,
the freezing process has an anesthetic,
anti-inflammatory effect on the treated tissue.
Cryo technology has advanced
as well. While once bulky, unwieldy
and slow, relying on liquid nitrogen,
the new device includes a small lap-
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cess involves a freeze-thaw-freezecycle that results in tissue destruction
through intra cellular ice formation,
causing cellular wall disruption, subsequent osmotic injury and delayed
micro vascular disruption leading to
tissue ischemia. The usual treatment
for sub four centimeter lesions takes
30 minutes.

Future Directions
In the pioneering study by Sabel
and colleagues, cryoablation was 100%
effective in tumors of any histology <
1.0 cm, and in tumors 1.0 – 1.5 cm
with pure invasive ductal or medullary
features without extensive intraductal
component.2 The Achilles’ heel is the
“image occult” disease, specifically
lobular and in situ carcinomas that do
not reveal their full extent on imaging.  
Magnetic Resonance Imaging (MRI)  
has emerged as the premier imaging
modality to document extent of disease in breast cancer.  To this end, the
American College of Surgeons Oncology Group is evaluating the sensitivity of MRI to detect residual disease
after a course of therapeutic cryoablation for sub 1.5 cm infiltrating ductal
carcinomas. While today we may not
be able to offer our case presentation
cryoablation for therapy, she is a candidate for the Cryo-Assisted Lumpectomy Trial, which uses the creation of
the ice ball intra-operatively to allow
for palpated excision of a non-palpable cancer.  The study endpoints are

percent of patients achieving negative
margin at index operation. Wthe final
results are yet to be realized, the interim analysis is promising.
In summary, as we look to the future of breast cancer therapy we have
reason to expect that detected tumor
size will continue to drop, and therefore the proportion of patients presenting with disease localized to the breast
will rise. We must find new modalities
to eliminate the disease with a minimum of morbidity to the patient.  As
we have abandoned axillary dissection
for sentinel node, so we may in a select
group of patients abandon wide local
excision for in-situ ablation.
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Advances in Pharmacology
Antidespressant-induced Weight Gain
Sarah Grace Kachur, PharmD, Christine L. Hannan, PharmD, and Kristina E. Ward, PharmD
Weight gain is a common concern
when treating patients with antidepressant medications.   The actual effects of
antidepressant medications on weight are
difficult to quantify because depression
is often characterized by changes in appetite, energy and physical activity.  The
propensity of an antidepressant medication to induce weight gain may be due
in part to its neuropharmacologic effects;
however, the mechanism for weight gain
caused by antidepressants cannot be
fully explained. Changes in weight vary
between classes of antidepressants, and between agents within each class.   
Weight gain is a frequent adverse effect of tricyclic antidepressants (TCAs)
and monoamine oxidase inhibitors
(MAOIs).  The antidepressant action of
MAOIs results from the irreversible inhibition of two monoamine oxidase enzyme isoforms, MAO-A and MAO-B.
Serotonin and epinephrine have a high
affinity for the MAO-A isoenzyme, while
dopamine, telemethylhistamine, and
phenylethylamine have a high affinity for
the MAO-B isoenzyme. Of the MAOIs,
phenelzine has been most associated with
weight gain; however, this conclusion is
based primarily on case reports.1 Another
MAOI, tranylcypromine, may cause
weight loss due to structural similarities to
amphetamines.1  
TCAs inhibit neurotransmitter
re-uptake at several sites, including serotonin, adrenergic and histamine receptors. The nonselective pharmacologic
actions of TCAs are the likely cause of
carbohydrate cravings, increased appetite,
and alterations in the regulation of body
fat stores.2,3  Although all TCAs are associated with weight gain, amitriptyline is associated with a higher likelihood of weight
gain than other agents within the class.  1,2
Selective serotonin reuptake inhibitors (SSRIs) have a more selective and
potent effect on serotonin than the less
selective activity of TCAs. However, the
mechanism of antidepressant action is not

entirely understood and is due to effects
other than the reuptake of serotonin at the
neurosynapse. 4 An increase in serotonin
availabiliy should decrease carbohydrate
intake and reduce cravings,3 but this effect
is unpredictable and poorly documented.
Slight pharmacological differences between SSRIs result in varying affinities for
serotonin, histamine and dopamine receptors, further complicating the association
between SSRIs and weight. In clinical trials, SSRIs have been associated with both
weight gain and weight loss.  

“...Patients
with appetite
suppression or
altered eating
habits caused by
depression are
more likely to
experience weight
change upon
treatment.”
Comparative Weight
Changes Between SSRIs
The largest trial prospectively com-

paring the metabolic effects of SSRIs was
conducted by Maina et al.5  Patients with
obsessive-compulsive disorder were randomized to treatment with clomipramine,
citalopram, fluoxetine, fluvoxamine, paroxetine or sertraline for 2.5 years.   Over
the course of the trial, mean body weight
increased by 1.58 kg (2.5%) compared
to baseline, with 14.5% of patients experiencing significant weight gain (increase
of 7% or more from baseline).  Patients in
the clomipramine group experienced the
highest mean percentage weight increase
(4.86%) and the highest proportion of
significant weight gain (34.8%); this is
consistent with the known adverse effects
of TCAs.  Fluoxetine patients experienced
initial weight loss, and were the only treatment group to not experience significant
weight gain over the course of the trial.  
The lowest proportions of patients experiencing significant weight gain were 8.7%
and 4.5%, in the fluoxetine and sertraline
groups, respectively.  Trial results are summarized in the table below.
In another prospective trial evaluating
long-term weight change, depressed patients were randomized to fluoxetine, sertraline, or paroxetine for 26 to 32 weeks.6
There was a small mean decrease in weight
(0.2%) among fluoxetine patients and

Table 1.5
Treatment Group
(daily dose range)

M e a n Pe r c e n t age Change at 6
Months*

Mean Percentage
Change at 30
Months*

Weight Gain
≥7% (%)

Clomipramine
(150-250 mg)
Citalopram
(40-80 mg)
Fluoxetine
(40-80 mg)
Fluvoxamine
(200-300 mg)
Paroxetine
(40-80 mg)
Sertraline
(150-200 mg)

0.89

4.86†

34.8

1.06

2.53†

14.3

-0.40

0.92

8.7

1.14

2.61†

10.7

1.43

2.59†

14.3

0.03

1.57†

4.5

*
†

Compared to baseline
P < 0.05 versus baseline
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a small mean increase in weight (1.0%)
among sertraline patients; neither change
was statistically significant.   Paroxetinetreated patients experienced a significant
increase in weight compared with baseline (3.6%).  From baseline to endpoint,
25.5%, 6.8% and 4.2% of paroxetine,
fluoxetine and sertraline patients, respectively, experienced 7% or greater weight
gain (P = 0.016 paroxetine vs fluoxetine, P
= 0.003 paroxetine vs sertraline).  
When fluoxetine was compared to
placebo for the prevention of relapse after
acute treatment of depression, fluoxetine
was associated with significantly more
weight gain than placebo over one year.7
After twelve weeks of acute treatment,
fluoxetine was associated with slight weight
loss (mean –0.35 kg, P < 0.01) from baseline weight.  After completion of the active
treatment phase, patients were randomized to 14, 26 or 38 weeks of continuation
fluoxetine therapy or placebo for relapse
prevention.   Among patients who completed the second phase of the trial, fluoxetine was associated with significant weight
increase over placebo after 14 (mean 1.1 kg,
P < 0.001), 26 (mean 2.2 kg, P < 0.001),
and 38 (mean 3.1 kg, P < 0.001) weeks of
continuation treatment.  Both fluoxetine
and placebo patients regained the weight
lost during the initial 12-week treatment
phase, and mean weight at the end of trial
was significantly higher than baseline in
both groups (mean 3.0 kg, P < 0.001).
Newer, non-SSRI antidepressants
have variable effects on weight.  A pooled
analysis of trials comparing nefazodone
to SSRIs demonstrated that nefazodone
is associated with fewer instances of significant (≥ 7%) weight loss in the acute
phase (6-8 weeks) of treatment.8 During
the long-term treatment phase (16-44
weeks), fewer nefazodone than SSRI
patients experienced significant (≥ 7%)
weight gain (8.3% vs. 17.9%, P = 0.003
for any point during treatment and
6.9% vs. 13.8%, P = 0.007 at endpoint).  
There was no difference between groups
in the incidence of significant weight
loss (≥ 7%) during long-term treatment.  
Fewer instances of weight loss during
the acute phase and weight gain during
long-term therapy suggest that nefazodone causes less weight variability than
SSRIs.
The weight gain associated with
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mirtazapine may be due to its activity
at histamine receptors.9  In a long-term
continuation of a trial of acute treatment, patients continued treatment
with mirtazapine, amitriptyline, or placebo for up to two years.10 Weight gain
was more common with amitriptyline
(22%) than mirtazapine (13%) patients,
but significantly more mirtazapine than
placebo patients experienced weight
gain. In a four-week study of healthy
subjects, those treated with mirtazapine experienced a significant increase
in body weight from baseline (mean
increase 3.64 lb.), suggesting that the
weight gain caused by mirtazapine is
independent of the weight changes associated with recovering depression.11 This
trial also quantified the changes in total
cholesterol, LDL and triglycerides associated with mirtazapine treatment. 11 After
four weeks of therapy, mirtazapine-treated subjects experienced a significant increase in total cholesterol (mean increase
7.6 mg/dL) and nonsignificant increases
in LDL and triglyceride levels compared
to baseline, while no significant changes
were noted in placebo-treated patients.
Among treated patients, weight increase
was linearly associated with increasing total cholesterol. The results of this
short-term trial suggest that weight and
cholesterol changes associated with mirtazapine occur independent of depression recovery.  
A small, open-label trial compared
the effects of mirtazapine and venlafaxine on weight.12 During the four weeks
of treatment, mirtazapine-treated patients experienced a mean weight gain
of 2.4 kg while venlafaxine-treated
patients had a mean loss of 0.4 kg.  A
twelve-week trial did not detect weight
change with either venlafaxine- or fluoxetine-treated patients.13 In another trial,
weight changes in elderly patients treated with venlafaxine or citalopram for six
months were not clinically significant.14
More research is needed to clarify the effects of venlafaxine on weight, although
the agent is most likely not associated
with significant weight gain or loss.
Bupropion is generally associated
with weight loss.  In an eight-week trial
comparing sustained release (SR) bupropion 150-400 mg/day to sertraline
50-200 mg/day, bupropion patients

experienced a mean 1.06 kg decrease in
weight from baseline to endpoint compared with 0.79 kg decrease for sertraline and a 0.21 kg increase for placebo;
these differences were not statistically
significant.15 During an eight-week placebo-controlled trial, bupropion SR 300
mg/day and 400 mg/day caused weight
loss greater than 5 pounds in 14% and
19% of patients, respectively, compared
with 6% of placebo patients.   Weight
loss of greater than 10 pounds occurred
in 2%, 6% and 2% of bupropion 300
mg, 400 mg and placebo patients.2
Discussion
Because of the difficulty separating
the effects of antidepressant medications
from the effects of depression, the
true effects of SSRI and non-SSRI
antidepressants on weight have yet to
be completely understood. In general,
SSRIs and other newer antidepressants
have a more favorable metabolic profile
than TCAs or MAOIs. Among SSRIs,
paroxetine is associated with weight
gain early in therapy but the longterm effects are unclear. Fluoxetine
may cause short-term weight loss that
resolves with continued treatment.
Other SSRIs are either weight-neutral
or the effects have yet to be determined.
Nefazodone appears less likely to cause
weight gain than SSRIs. Bupropion is
often associated with weight loss while
mirtazapine is associated with weight
gain and the effects of venlafaxine
remain unclear.
Several factors predict the
development of weight gain with
antidepressants.   Combination therapy
with multiple antidepressants or
an antidepressant and concomitant
antipsychotic may increase the risk of
weight gain, but the adverse effects may
counter each other (e.g., bupropion
and an SSRI).2   Patients with appetite
suppression or altered eating habits
caused by depression are more likely
to experience weight change upon
treatment.   The relationship between
higher daily dose and risk of weight gain
has not been evaluated.
When selecting an antidepressant,
the clinician must balance the risk
of weight change with the potential
benefits of  treatment.  Slight increases

in weight upon initial treatment may
resolve with continued therapy, but
significant weight change may decrease
medication compliance.
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A Physician’s Lexicon
The art and words of the apothecary
Shakespeare’s Romeo, referring to the lethal potion
that he is about to consume, exclaims: “O, true apothecary,
Thy drugs are quick.” The old-fashioned neighborhood
drugstore has long since been superseded by national chains
of markets selling all manner of health-related products;
and in the back of these emporia, typically, are teams of
apothecaries (now called registered pharmacists), dispensing a diversity of pills and solutions, although probably not
the rapidly-acting poisons of Shakespeare’s Veronese apothecary.
The word “apothecary” is derived from the Greek
root theca-, meaning storeroom and the Greek prefix, apo, meaning from or away from.  Thus the word originally
signified the contents of any treasure-house or store.  The
word apothecary, over the centuries, was modified to the
Spanish word, bodega (or sometimes bodetta) meaning a
storage place, or shop, for wines.   In Latin America, bodega has come to mean a neighborhood grocery store.  Yet
another derivative of apothecary was the old French word,
botica, which has evolved into the English word, boutique.
The word pharmacopeia, a registry or published
compendium of accepted medications, is derived from
the Greek, pharmicon, meaning drugs or the dispenser of

drugs, and a root, poi-, meaning to make or produce. This
latter root is found in the words poet and poetry.  The word
“drug” (as in drugstore) is Germanic in origin.   An older
word, droge, was used to describe any commercial products
which came in cases or barrels.
Apothecaries had once sold prepartions called philters,
or love potions. The word is a modification of the Greek
philo-, to love (as in words such as Anglophile or philosophy.)
The categories of medications include the febrifuges,
drugs to fight fever (from the Latin febris, meaning fever,
and fugo, meaning to flee); the anodynes, drugs to allay pain
(the Greek privative prefix, ano- and dinos, meaning pain),
the emollients, softening agents (Latin, mollis, meaning
soft), the cathartics (from a Greek word meaning to cleanse,
to purify, leading to such English words as catharsis and
Cathartist), the emetics (from a Greek word meaning to
vomit), and of course, the aphrodisiacs, named to honor
Aphrodite, the Greek goddess of love (the Greek root, aph‑
ros, meaning sea-foam, is a reminder that Aphrodite was
said to have arisen from the foam of the sea.)
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Advances in Laboratory Medicine
HPV Testing and Cervical Cancer Screening:
Recommendations and Practice Patterns
Lindsay M. Madom, MD, and Lori A. Boardman, MD, ScM
In several surveys of cervical
cancer screening practices among obstetricians and gynecologists in the
United States, discrepancies between
published guidelines and actual patient management have emerged.  For
example, in 1998, Suh-Burgmann
found that the majority of practitioners surveyed were performing repeat
smears at more frequent intervals than
recommended either by the American
College of Obstetricians and Gynecologists (ACOG) or the National
Cancer Institute (NCI).1  As recently
as 2005, Saint found that most gynecologists screen low-risk women often and indefinitely and that nearly
three-quarters would begin screening
virginal girls at age 18, despite national guidelines to the contrary.2 This
review  summarizes recent recommendations for cervical cancer screening
and discusses the role of high-risk or
oncogenic human papillomavirus
(HPV) testing as an adjunct to screening and in the management of women
with cytologic abnormalities.  
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Screening Guidelines:
Recent Changes
Although adolescents have a higher prevalence of abnormal screening
Pap smear results than adult females,
they are much more likely to experience regression of such abnormalities.  
As a result, the American Cancer Society (ACS) and ACOG recommend
that cervical cancer screening should
begin three years following the onset of
vaginal intercourse, but no later than
21 years of age.3 Discontinuation of
screening, on the other hand, should
occur for the majority of women undergoing total hysterectomy.  In 1996,
the US Preventive Services Task Force
recommended that routine cytologic
screening was unnecessary for women
who had undergone a complete hysterectomy for benign disease.4  Yet, in
2002, of the 22 million US women
who had undergone hysterectomy,
nearly half continued to undergo Pap
smear screening unnecessarily.5 A similar scenario is seen with screening pracMedicine and Health / Rhode Island

tices among elderly women.  Although
the ACS recommends that women 70
years of age and over who have had at
least three technically satisfactory and
normal Pap smears and no abnormal
smears in the last 10 years may choose
to stop cervical cancer screening,6
nearly half of women aged 65-74 are
screened for cervical cancer annually.7
Providers continue to perform
annual screening for numerous
reasons.  Noller19   speculated that
one of the major reasons driving annual cervical cytology occurred with
the introduction of oral contraceptives (OCPs). Physicians linked annual screening to continuation of oral
contraceptives, thus leading to the
idea that every annual included a Pap
smear.  Some may also adhere to older
guidelines; some are uncomfortable
not screening sexually active adolescents; some are worried women won’t
return for an annual visit if a Pap is not
done on a yearly basis.

“… data suggest
that combined
testing with both
cytology and
high-risk HPV
typing is superior
to cytologic
surveillance
alone.”
HPV Typing in Screening
High-risk or oncogenic HPV is a
necessary cause of nearly all high-grade
cervical neoplasia and squamous cell
cancer of the cervix.  However, only a
fraction of the women with evidence
of high-risk HPV infection in the US
will develop cancer.  While repeatedly
negative cervical cytologic results are
reassuring, particularly in women aged
30 and over for whom screening inter-

vals may then be increased,6 data suggest that combined testing with both
cytology and high-risk HPV typing is
superior to cytologic surveillance alone
in this population.   In a number of
studies, combined HPV testing with
cervical cytology resulted in negative
predictive values for CIN 2 and CIN 3
of 99-100% .8-13  Specificity, however,
of the combined tests remained lower
than that for cytology alone.
Based on such evidence, the NCI,
the American Society for Colposcopy
and Cervical Pathology and the ACS
issued interim guidelines recommending the use of a combination of cervical cytology and HPV DNA screening in women aged 30 and over ,14 a
recommendation ACOG endorsed in
2005.15   Today’s commercial probes,
designed to identify 13 oncogenic
HPV subtypes, are sandwich capture
molecular hybridization assays that
utilize chemiluminescent detection.   
The intensity of light measured is
proportional to the amount of target
DNA in the specimen, with a positive test defined as a relative light unit
measurement of ≥1 pg/ml HPV DNA
(or 5,000 genomic DNA equivalents).  
HPV DNA testing as an adjunct to
cytology is expressly not recommended for women under 30, as the high
prevalence and transitory nature of
this infection render such a paradigm
both ineffective and costly.16  The decreasing prevalence of HPV in women
older than 30 years, together with the
high negative predictive value cited
above, make the combination of HPV
typing and cytology the most practical
screening regimen for this age group.  
In terms of management, if both
cytology and HPV typing are negative,
the patient may safely undergo similar
screening in 3 years.   For those with
negative HPV typing, but abnormal
cervical cytology, two situations arise.  
If the abnormality is ASC-US, repeat
cytology testing is recommended in
12 months.   For any other cytologic
abnormality, colposcopy is recommended.   On the other hand, if a
woman has ASC-US and is found to

be HPV positive, she should undergo
colposcopy as well.  The most difficult
clinical issue that arises, however, has
been the triage of a woman with negative cytology, but a positive high-risk
HPV test.   Because the risk of CIN
2 or worse is low, both tests should
be repeated in 6 to 12 months.   For
those with evidence of persistent HPV
infection but negative cytology, colposcopy is warranted.14   Clearly, questions arise regarding further management, including the possible need for
treatment of persistent HPV infection
coupled with negative cytology and no
evidence of neoplasia on colposcopic
examination.  At present, however, the
rationale for treatment is unjustified.
HPV Typing in
Management of Cytologic
Abnormalities
Oncogenic HPV testing is used in
two other clinical situations: as a triage
method for ASC-US and as a test of
cure for women following therapy for
CIN 2 or CIN 3.15   Although HPV
DNA testing was not found to be
helpful in the management of LSIL,
investigators have demonstrated that
among women with ASC-US, reflex
HPV typing, compared to a single repeat cervical cytology at 4-6 months,
was significantly more sensitive for the
detection of histologically diagnosed
CIN 3 or worse.17    Although the traditional scheme of two repeat cytologic
evaluations was subsequently reported
to be similar in sensitivity to reflex
HPV testing, the latter is preferred in
settings where liquid-based cytology is
used due to its cost-effectiveness.15  If
HPV testing is found to be positive,
the patient is referred to colposcopy,
while a negative HPV allows for return to annual cytologic screening.  Of
note, adjunct HPV typing is not recommended for ASC-H, LSIL or worse
or any glandular abnormality, as such
patients require colposcopy.
Finally, in a meta-analysis of 11
studies evaluating oncogenic HPV
typing in monitoring women treated
for CIN 3, combined testing with
high-risk HPV and cytology at 6
months following therapy proved
more effective in predicting persistent
CIN than either test alone or resection
margin status.   From studies to date,
70% of women treated for CIN 3 will
test negative on both HPV testing and
cytology at 6 months follow up,18 and

further monitoring may be less intensive.  
Summary
In summary, guidelines for cervical cancer screening continue to
evolve, as knowledge of the pathogenesis of the disease as well as the role
of HPV expands.    Oncogenic HPV
typing has proven effective in cancer
screening and follow-up in certain
situations, and its uses will undoubtedly increase.   Patients and providers
may be reassured with negative HPV
testing, but long term management
of positive HPV testing (especially in
conjunction with negative cytology) is
unclear.  At present, however, numerous worldwide, prospective studies involving HPV testing and cervical cancer screening will, we hope,   provide
some of the answers regarding optimal
management of women who remain
persistently HPV positive.     
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Overweight and Weight Control among
Rhode Island Girls and Women, 2003
Jana E. Hesser, PhD, and Donald K. Perry, MPA
Reducing the proportion of Rhode
Island adults who are obese and reducing the proportion of Rhode Island youth
who are overweight and obese are Healthy
Rhode Islanders 2010 (HRI2010) objectives.1,2   HRI2010 strategies promote
increased physical activity and increased
fruit and vegetable consumption.2
This paper presents data for Rhode
Island girls and women on overweight/
obesity, weight control strategies, physical activity, and fruit and vegetable consumption based on two Rhode Island
surveys performed in 2003 -- the Behavioral Risk Factor Surveillance System
(BRFSS) and the Youth Risk Behavior
Survey (YRBS).
Methods
The BRFSS is a telephone survey of
randomly selected non-institutionalized
adults ages 18 and older.  It is administered in all 50 states and 4 US territories
with funding and methodological specifications provided by the federal Centers
for Disease Control and Prevention
(CDC).3   In 2003, RI’s BRFSS interviewed 4,053 RI adults.
The YRBS is an anonymous and
voluntary survey conducted in alternate
years among randomly selected high
schools and students.  The CDC sponsors the YRBS in states and localities
nationwide.4 In spring 2003 the Rhode
Island Departments of Education and
Health administered the YRBS to 1,814
Rhode Island public school students in
grades 9 through 12.
In 2003 both the Rhode Island

BRFSS and YRBS collected information
about height and weight, which are used
to calculate body mass index (BMI);
participation in physical activity; fruit
and vegetable consumption; and weight
control efforts.  
The two surveys asked similar questions about weight control efforts -- Are
you now trying to lose weight? Are you
now trying to keep from gaining weight?  
Are you eating fewer calories or less fat
to lose or maintain weight?  Are you exercising to lose or maintain weight?   In
addition, the YRBS asked about several
high-risk weight loss behaviors that adolescents may use.
For both surveys CDC derives two
variables for physical activity and one
measure for fruit and vegetable consumption.   For physical activity the variables
are: “meets guidelines for recommended
level of moderate or vigorous physical
activity” (30 minutes a day five or more
days a week, or 20 minutes or more of
vigorous physical activity 3 or more days
a week); and “engages in no physical activity.”   The dietary measure is “meets
guidelines for fruit and vegetable consumption” (five or more servings of fruits
and vegetables a day).   Prevalence estimates for all variables were calculated for
high school girls (YRBS), and for women
in four age groups (BRFSS).
Results
The proportion of females who are
overweight increases with age, from 21%
of adolescents who are at risk for overweight or overweight, to 32% of wom-

en ages 18 – 24 who are overweight or
obese, up to 56% of women ages 65 and
older.  While 21% of girls are at risk for
or overweight, 35% describe themselves
as slightly or very overweight. (Table 1)
Eighty percent or more of girls and
women up to age 64 and 75% of those 65
and older are either trying to lose weight
or keep from gaining weight.  Sixty-one
percent of girls and nearly half of all
women are trying to lose weight. (Table
2)  Three times as many girls are trying
to lose weight as are at risk or overweight,
and 50% more women ages 18 – 24 are
trying to lose weight than are overweight
or obese.
Half or more of girls and women up
to age 64 and one-third of women ages
65 and older are using both calorie restriction and physical activity to lose or
maintain weight.  The proportion using
dieting alone increases with age from 7%
of girls to 36% of women ages 65 and
older, while the proportion using exercise
alone decreases from 23% of girls to 9%
of women ages 65 and older. (Table 2)
The YRBS also asked girls about
high risks behaviors to lose or maintain
weight; e.g.,  fasting for 24 hours or more
(17%); using diet pills, powders or liquids without a doctor’s advice (8%); and
vomiting or using laxatives (6%). (Table
2)
High school girls and women ages
18 – 24 have the lowest proportion (26%)
meeting the recommended fruit and vegetable guidelines.  Women 65 and older
have the highest percentage meeting this
guideline (41%). (Table 3)

Table 1. Overweight and Obesity among High School Girls and Women Ages 18 and Older,
Rhode Island 2003
Girls
Women
Ages
Ages
Ages
Ages
Ages
Weight Measure
Grades
18-24
25-44
45-64
65+
18+
9–12
At risk of overweight*
15%
Overweight**
21%
25%
31%
40%
30%
Overweight***
6%
Obese****
11%
18%
23%
16%
18%
Self–perceived overweight
35%
NA
NA
NA
NA
NA
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* At or above the 85th percentile but below the 95th percentile for BMI for age and sex based
on data from the National Health and Nutrition Examination Survey I (NHANES I)5
** BMI >25 and <30
*** At or above the 95th percentile for BMI for age and sex based on NHANES I
**** BMI >30
Medicine and Health / Rhode Island

Table 2. Strategies and Objectives for Losing or Maintaining Weight among High School Girls and
Women Ages 18 and Older, Rhode Island 2003.
Girls
Women
Ages
Ages
Ages
Ages
Ages
Weight Control
Grades
18-24
25-44
45-64
65+
18+
9–12
Objective:
Lose weight
61%
48%
49%
56%
40%
49%
Maintain weight
19%
37%
38%
32%
35%
36%
Weight loss strategy (for those trying to lose or maintain weight):
Just fewer calories/less fat
7%
13%
17%
26%
36%
23%
Just exercise
23%
22%
16%
8%
9%
13%
Both fewer calories and exercise
58%
52%
55%
58%
38%
52%
Fasted 24 + hours
17%
NA
NA
NA
NA
NA
Took diet meds*
8%
NA
NA
NA
NA
NA
Vomited/took laxatives
6%
NA
NA
NA
NA
NA
*Without doctor’s advice

Girls (60%) and women ages 18
– 24 (57%) have the highest proportion
meeting the recommended guidelines
for moderate or vigorous physical activity.  The proportion declines with age, to
28% for women ages 65 and older.  Only
10% of girls do not participate in any
moderate or vigorous physical activity
while the proportion of women who do
not participate in any leisure time physical activity increases from 21% of those
ages 18 – 24 to 40% of women ages 65
and older. (Table 3)
Discussion
Addressing the epidemic of overweight and obesity in the US requires,
in part, the individual intention to manage weight.  Three quarters or more of
Rhode Island girls and women surveyed
in 2003 were trying to lose or maintain
their weight, which may suggest a healthy
intent.   However, with the exception of
women over age 65, a higher percentage
of females, especially girls, are trying to
lose weight than are actually estimated to
be overweight, which signals a potential
health risk.  
Close to 90% of girls and women
trying to lose or maintain their weight
report doing so by restricting calories or
fat, by exercising, or both.   While a high
percentage report that they exercise to
control weight, a lower percentage report
participation in the recommended level

of either moderate or vigorous physical
activity. A difference of about 20 percentage points between the two estimates is
consistent across all age groups.
Likewise, the low proportion of girls
and women eating the recommended 5
or more servings of fruits and vegetables
is discrepant with the high proportion
saying they are eating fewer calories or
less fat to manage their weight.    
Several observations from this analysis can inform public health interventions
designed to address the obesity “epidemic.”   First, the discrepancy between the
high level of weight management actions
of girls and women and their reported
physical activity and fruit and vegetable
intake practices suggests greater effort is
needed to help the public recognize the
amount of exercise and types of food that
can be most effective for weight management.  Second, the use of some risky
weight loss practices by high school girls
may indicate a low salience of health concerns in their choice of weight reduction
and maintenance strategies.  There is need
to reinforce public health messages about
the health-related risks of overweight and
obesity and about healthy exercise and
dietary weight loss strategies.  Given the
large proportion of girls and women trying to lose weight who may not actually
be overweight, efforts must also address
when it is appropriate and healthy to engage in weight loss strategies.

Jana Hesser, PhD, is Program Man‑
ager for Health Surveys and BRFSS Project
Director, Center for Health Data and Anal‑
ysis, Rhode Island Department of Health,
and Clinical Assistant Professor in Com‑
munity Health, Brown Medical School.
Donald Perry, MPA, is Health Policy
Analyst, Center for Health Data and Anal‑
ysis, Rhode Island Department of Health,
and Manager for school-based surveys.
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Table 3. Weight-Related Health Behaviors among High School Girls and Women Ages 18 and Older,
Rhode Island 2003.
Girls
Women
Weight-Related
Ages
Ages
Ages
Ages
Ages
Grades
Health Behavior
18-24
25-44
45-64
65+
18+
9–12
Diet:
Meet guidelines of 5 or more
26%
26%
31%
30%
41%
32%
servings of fruits and vegetables per day
Physical Activity:
Meet guidelines for recommended
60%
57%
55%
48%
28%
53%
moderate or vigorous physical activity
Does not participate in physical activity
10%
21%
25%
28%
40%
28%
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Rhode Island Department of Health Office of Women’s
Health: A Gender Focus to Improve Health Status
Nancy Libby-Fisher, MMHS
The concept of women’s health,
traditionally, has focused on reproductive health and breast and cervical
cancer.  This view has changed in the
last decade to encompass the physical,
mental, social, and economic factors
that influence women’s health status
across their lifespan.  
Women’s health is devoted to facilitating the preservation of wellness
and the prevention of illness in women
and includes screening, diagnosis, and
management of conditions which are
unique to women; are more common
in women; are more serious in women;
and have manifestations, risk factors
or interventions which are different in
women.1
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Health Status of Rhode
Island Women
The Office of Women’s Health was
created in 2001 to provide a genderinformed approach to programs and
services within the Rhode Island Department of Health to eliminate health
disparities and improve the health status of Rhode Island women and girls.  
Health disparities for Rhode Island women are not solely a factor of
gender.   In addition to gender differences in health status, there are also
substantial differences between women
in Rhode Island compared to women
nationally, in Rhode Island women as
they age, and among different racial or
ethnic groups.  
Tobacco use in Rhode Island
among adolescent girls, for example,
is higher than among adolescent boys.  
About one in four women smoke and
rates are similar for female high school
students.   A higher proportion of female students smoke than male students, with the greatest difference occurring in the 9th grade.2  
Rhode Island women self-report
a higher rate (11%) of asthma than
Rhode Island men (6%), and the rate
for RI women is higher than the median for US women (9%).3
Physical activity decreases as womMedicine and Health / Rhode Island

en age.   Regular physical activity has
been shown to reduce the risk of death
from heart disease, lower the risk of
developing diabetes, help prevent high
blood pressures, and is associated with
a decreased risk of colon cancer.   Yet
fewer than one woman in four (at any
age) gets the minimum recommended
amount of physical activity and the
percent of Rhode Island women who
are active decreases with age.4
Overweight and obesity are associated with 54 co-morbid diseases.   Although all women may be at risk, minority women are disproportionately
affected.   State data   show that more
than half of all Rhode Island women
are overweight or obese. Hispanic and
Black non-Hispanic women are more
likely to be overweight than White
non-Hispanic women, and minority
women are more than twice as likely to
be obese. 5
Office of Women’s Health
The health status of men and
women differ in many areas.  Genderneutral policies assume that everyone
is affected by programs in the same
way.  The same interventions, however,
do not necessarily yield equal results;
different treatments may sometimes
be required to achieve similar results,6
and the Office works with programs to
identify areas where targeted efforts are
needed.
Among its responsibilities, the
Office hosts an annual statewide
conference on women’s health.   Past
conferences have focused on women
65 years of age and older, women in
midlife from 45 – 64 years of age, and
women of reproductive age between 18
– 44 years.  This year the conference
will focus on adolescent girls aged 11
– 17. “The Face of Health: Risk and
Resiliency in Adolescent Girls” will be
held at the Holiday Inn in Providence
on November 15, 2005.  Co-sponsors
include the Health Department’s Division of Family Health, Brown University/Women & Infants Hospital Cen-

ters of Excellence in Women’s Health,
and the Rhode Island Department of
Education.  Pre-registration is required;
the cost is $25.
The Office is assisted by an Internal Work Group comprised of representatives from all of the Department’s
Divisions.  This group improves internal coordination among program areas,
provides information, and addresses areas where there are significant disparities in the health of RI women.
For more information about the
Office of Women’s Health visit:
http://www.health.ri.gov/disease/
owh/index.php
Osteoporosis Program
The Office of Women’s Health is
primarily a policy office, but it does
have overall responsibility for the Department’s Osteoporosis Program. In
Rhode Island, the prevalence of osteoporosis and low bone mass for those
over 50 years of age is 129,100 women
and 53,500 men.7
The Osteoporosis Program Manager works closely with and staffs the
RI Osteoporosis Coalition.   The Department of Health and the Coalition
share the goal of reducing osteoporosis
in Rhode Island.  Collaboratively they
implement public awareness campaigns
to educate people about the risks of osteoporosis and encourage them to talk
with their doctor about this disease.  
Campaigns include osteoporosis education classes, bone density screenings,
and distribution of educational materials at community health fairs.  
A goal of the program is to reduce
the number of undiagnosed cases of
osteoporosis and increase treatment.  
Professional education efforts include
articles about osteoporosis in Medi‑
cine & Health/Rhode Island and grand
rounds at local hospitals.  On October
1, 2005, the Coalition held the Osteoporosis Workshop for Physicians at the
Marriott Hotel in Providence.
The Osteoporosis Program routinely assesses the status of osteoporo-

sis in Rhode Island by means of the
state’s annual Behavioral Risk Factor
Surveillance System (BRFSS),   a random telephone health survey of Rhode
Island adults.   Some of the questions
ask about the information these individuals receive from their doctor or
health care professional.  The practice
of doctors and health care providers is
evaluated by asking survey participants
questions pertaining to any discussion
they recall with their doctor about the
risks of osteoporosis, the need for calcium and vitamin D, and the recommendation for a bone mineral density
test.  In 2005 questions were included
to estimate the prevalence of osteoporosis in Rhode Island.
Information about the Osteoporosis Program can be found on the Department’s website: http://www.health.
ri.gov/disease/osteo/index.php
		
Women’s Health Advisory
Committee
The Office of Women’s Health is
guided by the Women’s Health Advisory Committee whose members are appointed by the Director of Health and
represent women from diverse areas of

the state, ages, professions, ethnic and
racial groups, and abilities.  The Advisory Committee provides leadership in
setting priorities, makes recommendations to the Director of Health, advises
on policies and programs that impact
women, and increases the visibility of
women’s health issues.  In its efforts to
develop a coordinated, comprehensive
health system for women in Rhode Island, it has enlisted the input of women
throughout the state in their work, collaborated with other organizations and
agencies, conducted public forums,
and targeted areas of concern.  
An Advisory Committee priority is
health literacy.  Health literacy seems to
affect women more than men.  Women
who live in poverty or have less than
a high school education have shorter
life spans, higher rates of illness, injury,
disability and death, and more limited access to high quality health care
services.   There is a high correlation
between lower literacy levels, poverty
and poorer health status. This creates
an even greater burden since women,
in addition to caring for their health
needs, often function as gatekeepers for
the health care of their families.
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Are Older Rhode Island Women Receiving
Appropriate Screening for Breast Cancer?
Johanna Bell Butler, MPH, Maureen Claflin, RN, MSN, Deidre S. Gifford, MD, MPH
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Recent data from the 2004 national Behavioral Risk
Factor Surveillance Survey (BRFSS), a population-based
telephone survey conducted by the Centers for Disease
Control and Prevention (CDC), show that Rhode Island
women over the age of 40 tied with women in Massachusetts
and Delaware for the highest rate of self-reported biennial
mammography screening in the country, at 82.4%.1  The
national average rate was 74.6%.  Achieving the nation’s
highest percentage of women 40+ obtaining screening
mammograms is a tremendous accomplishment for Rhode
Island. Clearly, the Rhode Island medical and public
health communities are doing a great job at promoting
mammography screening.
These self-reported data contrast sharply with the rates
seen when examining actual claims for mammography.
(Figure 1)  As part of its work as the Quality Improvement
Organization for the state, Quality Partners of Rhode
Island tracks Medicare claims for screening mammography
in women aged 50-69.  Over a similar time frame, Rhode
Island women with Medicare, aged 50-69,  have a much
lower screening rate when claims are used as a data source.
Of the 8,686 female Medicare beneficiaries aged 50-69,
only 5,124 (59%) had a claim filed for a mammogram
from 2002-2004.  Further, this rate is a decline from the
61.1% who had a mammography claim in the 1999-2001
timeframe.   In contrast, the self-reported rate in BRFSS
for women 65 and over was 84.7%, and for women aged
60-64 was 87.8%.  
Literature demonstrates that Medicare claims data may
underestimate the number of mammography screenings
through a combination of lost claims, self-pay or use of
alternate payers, and free programs.2,3,4 One study in
Colorado found that Medicare claims data underestimated
true screenings by 15%.4 With Rhode Island claims
rates at only around 60%, one might assume that a true
mammography screening rate for this population hovers
somewhere around 75%, indicating that one in four
women in this high-risk group is not seeking or receiving a
screening mammography.
In contrast, there is some suggestion that BRFSS
may over-report mammography screening due to “social
desirability bias” which leads women to over-report having
a test that they recognize as recommended. The magnitude
of this potential bias, and its accompanying over-reporting
in BRFSS, is unclear. Further, self-report of “ever having a
mammogram” is probably more accurate than rates which
pertain to a particular time period, as women may state
that a mammogram has occurred in the last two years
when in fact it occurred outside of that time frame.5  While
Medicare claims may under-report the actual screening
rate, and BRFSS possibly over reports that rate, one can
conclude that there is still a substantial portion of the
Medicine and Health / Rhode Island

Medicare population in Rhode Island, somewhere between
15-25%, who are not receiving the appropriate screening
for breast cancer.  
According to claims data Rhode Island has achieved
little success in increasing the percentage of women on
Medicare who obtain screening mammograms since 19912004,  despite the fact that mammograms are fully covered
by Medicare.   National claims-based rates also declined,
from   59.7% to 59.1% in the same period. Intensive
interventions targeting this age group in Rhode Island have
yielded little improvement. A three-year, multi-pronged
intervention implemented by Quality Partners included
direct mail and incentives, physician referral and follow-up
assistance, outreach to senior centers, media advertisements,
and a facility wait time survey/physician awareness effort.  
According to National Cancer Institute Surveillance
and the American Cancer Society, breast cancer risk increases
with age. Not only is the incidence of breast cancer higher
in older women, but older women are more likely to present
with advanced breast cancer at diagnosis than younger
women.6,7 Screening mammography has been shown to
reduce mortality from breast cancer by 20% to 39% among
women aged 50 and older.8   Rhode Island women on
Medicare are fully covered for mammography screenings
(although they must pay a small co-pay), face increased risk
according to age, and yet a substantial number do not get
screened. What are the root causes for this gap, and what are
the local challenges for helping to improve these rates?

Studies have repeatedly demonstrated that physician
referral is the primary catalyst motivating women to seek
mammograms.9,10,11 As part of a mammography screening
campaign Quality Partners developed a physician referral
and follow-up tool consisting of a two-part form to assist
providers in monitoring and following-up when a patient
fails to obtain a mammogram after referral. We have found
that few offices have systems which allow them to track
patients who are due or overdue for screening, few offices
notify women who are overdue for the test, and many do not
have systems to follow-up after a screening mammogram
has been ordered to be sure that it has occurred.   With
the growing emphasis on electronic medical records and
disease registries, more and more practices should be able
to develop these capabilities.  
Our survey of Rhode Island mammography screening
facilities found that screening appointment wait times
ranged from 1 day to 150 days, with few facilities sending
reminder cards or letters to women who are due for a
mammogram. Women referred by their doctors to a
specific facility, and discovering a wait time of several weeks
or months, may be failing to make an appointment or keep
the appointment that is scheduled too far in advance.
Quality Partners received positive feedback from Rhode
Island physicians who, upon receiving the wait time survey
result, were made aware of the delays for the first time and,
equally important, learned of the existence of other facilities
with little or no wait time that were equally convenient for
their patients. Scheduling appointments for screenings is
an important component of patient compliance, especially
since Rhode Island lacks mobile facilities which allow for
on-site visits to senior centers, elderly housing sites, etc.
Women on Medicare may face unique challenges
that impact on their likelihood to seek screening
mammograms. Some women still are not aware of their
need to be screened.12 Women under age 65 on Medicare
face co-existing morbidities that qualify them for the
program at a younger age. These health conditions may
limit their independence and/or mobility. Additionally, the
day-to-day demands of managing competing morbidities,
including physician visits, treatments, medications, and
tests, can push preventive screenings into low priority
and even cause patients to question the utility of “looking
for more problems.” These patients require additional
encouragement and explanation by their physicians to raise
the issue of mammography screening to a more compelling
level.
Women over age 65 still need to receive annual
screening mammography. Clinical practice guidelines for
mammography recommend annual screenings for women
age 50-69. There is currently no evidence citing an age at
which women fail to benefit from screening mammography.
Most guidelines recommend that physicians evaluate such
factors as competing morbidity, life expectancy and ability
to undergo treatment in determining whether to refer
female patients over 70 for mammography screenings.13
The Rhode Island medical and public health
community has a proud record of promoting and
facilitating annual mammography screenings for women
over 40. Yet the data continue to point to a significant
proportion of those on Medicare who have not shared in
the improved mammography screening rates despite full

coverage for mammography screening and increased risk
for breast cancer.   Special attention must be paid to the
needs, barriers, and challenges faced by women in this
group in order for the state to truly meet its mammography
screening goals in the next two-year period and beyond.
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doomed extremity”], 4 were failures [”loss
of limb”].
Herbert Fanger, MD, in “Long
PER YEAR $2.00
VOLUME 1
Term Survival in Cancer of Breast,
SINGLE COPY, 25 CENTS
PROVIDENCE, R.I., JANUARY, 1917
NUMBER 1
Stomach and in Malignant Melanomas,”
traced 5 year survival over distinct spans.
From 1932-35, of 142 cases, 14% lived
Ninety Years Ago, October 1915
at least 5 years. The survival rate peaked in 1941-45: of 160 cases,
An Editorial urged physicians to take vacations, even though
31% met the 5-year goal. By 1946-48, the rate had dropped to
patients may object to the physician’s absence: “When we find a
25% (98 cases).
patient tired out from overwork or protracted work, we appreciate
Seebert Goldowsky, MD, continued with “The Beginnings
the futility of our medical armamentarium, and we advise him to
of Medical Education in Rhode Island, Part 11.” In 1822 Brown
take a vacation, and it is the good doctor who prescribes a vacation
launched a medical program, paying faculty stipends for partfor himself as well as for his patient.”  The same Editorial laments
time lecturing ($10-15 for a 3-month, once-a-month lecture
the ungrateful patient: “The time was when we could show with
series). Rev. Francis Wayland, Jr, who became president in
pride a silver loving cup, a gold watch…but these instances are
1828, effectively ended the medical program by abolishing the
now so rare that they are to be regarded as a curiosity of medical
faculty positions. President Wayland replaced Asa Messer; and
life and not an essential part of it.”
the corporation charged this new president with improving the
W.H. Peters, MD, discussed “Carelessness in Physical
University. Dr. Goldowsky analyzed the decision to bar off-site
Examinations for Life Insurance.” Dr. Peters confessed: “I have
faculty as “incidental” to strengthening the University, not part of
witnessed life insurance examinations for good-sized policies
an express intent to end the medical curriculum.  
by medical men of repute that were all pure bunko….they pass
over in their reports a heart a little wobbly or a little sugar in the
Twenty-Five Years Ago, October 1980
urine, and so on.” The reason for the laxity: salesmen were paid on
Guy A. Settipane, MD, discussed “Anaphylactic Reactions
commission, hence steered applicants to lax examining physicians:
in
Asthmatic
Patients.” The “likelihood of significant reactions
“…the careless examiner may lose a little sleep in worrying over his
depend upon the specific immunological mechanisms involved.”  
reports, but is able to console himself with the larger share of the
Eugene G. Laforet, MD [Chief of Thoracic Surgery,
assignment.”
Newton-Wellesley Hospital], and Robert L. Berger, MD [Chief of
Cardiothoracic Surgery, University Hospitals, Boston), contributed
Fifty Years Ago, October 1955
“The Use of the Celestin Tube in Complicated Esophageal
Stewart Armstrong, MD, Instructor in Surgery, Boston
Problems.” They asserted: “The device may be palliative or curative
University School of Medicine, contributed “Segmental Arterial
in a variety of different situations.” Of 20 patients discussed (9
Occlusions Treated with Resection and Grafting.” Of ten cases
with malignant neoplasms), “no patient died as a direct result of
discussed, 6 had a “good result” [“preservation of the already
the operative procedure.”
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Live Births
Deaths
Infant Deaths
   Neonatal deaths
Marriages
Divorces
Induced Terminations
Spontaneous Fetal Deaths
Under 20 weeks gestation
20+ weeks gestation
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V i t a l S t a t i stics
Edited by Roberta A. Chevoya, State Registrar

Diseases of the Heart
Malignant Neoplasms
Cerebrovascular Diseases
Injuries (Accident/Suicide/Homicide)
COPD

Reporting Period
April
2005
Number
1350
824
(10)
(8)
463
207
455
84
(76)
(8)

12 Months Ending with
April 2005
Number
Rates
13,533
12.7*
10,181
9.5*
(84)
6.2#
(68)
5.0#
8,069
7.5*
3,176
3.0*
5,437
401.8#
1,016
75.1#
(933)
68.9#
(83)
6.1#

Reporting Period
October
2004
Number (a)

221
222
39
45
31

12 Months Ending with October 2004
Number (a)

2,989
2,479
491
459
461

Rates (b)

279.4
231.7
45.9
42.9
43.1

YPLL (c)

4,574.0
6,919.0
822.5
7,119.5
372.5

(a) Cause of death statistics were derived from the
underlying cause of death reported by physicians on
death certificates.
(b) Rates per 100,000 estimated population of
1,069,725
(c) Years of Potential Life Lost (YPLL)

Note: Totals represent vital events which occurred in Rhode Island
for the reporting periods listed above. Monthly provisional totals
should be analyzed with caution because the numbers may be
small and subject to seasonal variation.
* Rates per 1,000 estimated population
** Excludes one death of unknown age.

# Rates per 1,000 live births
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